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TOM BRODY
ABSTRACT
Claims in patents include both structural elements and functional elements. Functional elements
occur in various categories: (1) Functional elements that mandate a particular range of structures
that are able to perform the required function; (2) Functional elements that mandate a particular
cooperation between structures; (3) Compound noun/function functional elements, (4) Active-type
functional elements; (5) “Capable of”-type functional elements, (6) Single-word structural elements
that are typical nouns, but that are also functional elements, e.g., “plasticizer,” and (7) Quasifunctional elements that lack any patentable weight. This article discloses which of these types of
functional elements confers the broadest claim scope, and which are most resistant to rejections
under 35 U.S.C. § 102 or 35 U.S.C. § 103. The author also announces the discovery of a paradox in
patent law, namely, the Newman Paradox, and compares it with another paradox, the Wands-Vaeck
Paradox. This article describes two different traps, which can result from a failure to understand
the proper construction of functional elements. These traps are The Hough/Hovath Trap, and The
Trap of In re Robertson. This is the first article to provide an in-depth analysis of cases from the
Patent Trial and Appeal Board (“PTAB”), previously known as the Board of Patent Appeals and
Interferences (“BPAI”) (“Board”).
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FUNCTIONAL ELEMENTS IN PATENT CLAIMS, AS CONSTRUED BY THE
PATENT TRIAL AND APPEAL BOARD (PTAB)
TOM BRODY*
I. INTRODUCTION
Patents contain two sections, the specification and the claims. 1 The claims
identify the intellectual property, while the specification contains background
information useful for defining the words in the claims and for providing guidance for
making and using the invention.2 Mainstream concerns in patenting include
determining the persons to be named as inventors, 3 determining the date of
conception and the patent’s priority date, 4 drafting working and prophetic examples
for the specification,5 claim drafting,6 duty to disclose,7 foreign filing strategies,8
* © Tom Brody 2014. The author received a Ph.D. in biochemistry in 1980 from University of
California at Berkeley. The author is a patent agent at a California office of a national law firm and
has prosecuted over 150 patent applications, e.g., in biotechnology, medical devices, and chemical
engineering. The author is also the author of two textbooks: NUTRITIONAL BIOCHEMISTRY (1999)
and CLINICAL TRIALS: STUDY DESIGN; ENDPOINTS & BIOMARKERS; DRUG SAFETY; FDA & ICH
GUIDELINES (2012), each published by Elsevier/Academic Press. The opinions expressed herein do
not necessarily reflect those of the author’s present, past, or future employers, and do not constitute
legal advice. This article does not establish or suggest any relationship between the author and the
reader. The author thanks John S. Hilten, J.D. for reviewing the manuscript. The author also
thanks Dr. Adam D. Sussman, Ph.D. for his inspiring comments on the manuscript.
1 35 U.S.C. § 112(a)–(b) (2012).
2 35 U.S.C. § 112(a)–(b); 37 C.F.R. § 1.71 (2013); 37 C.F.R. § 1.75 (2013); U.S. PAT. &
TRADEMARK OFFICE, U.S. DEP’T OF COMMERCE, MANUAL OF PATENT EXAMINING PROCEDURE
§ 608.01 (8th ed. Rev. 9, Aug. 2012) [hereinafter MPEP].
3 Dale L. Carlson & James R. Barney, The Division of Rights Among Joint Inventors: Public
Policy Concerns after Ethicon v. U.S. Surgical, 39 IDEA 251, 257 (1999); David Hricik, Alexandra
Geczi & Zachary Thomas, Save a Little Room For Me: The Necessity of Naming as Inventors
Practitioners Who Conceive of Claimed Subject Matter, 55 MERCER L. REV. 635, 636 (2004).
4 Paula K. Davis & Steven P. Caltrider, Timing (of Invention) is Everything: The Essential
Role of the Written Description Requirement in Determining Conception, 15 FED. CIR. B.J. 39, 40
(2005); Mark A. Lemley & Colleen V. Chien, Are the U.S. Patent Priority Rules Really Necessary?,
54 HASTINGS L.J. 1299, 1300 (2003); Charles L. Gholz, A Critique of the New Rules and the New
Standing Order in Contested Case/Interference Practice, 87 J. PAT. & TRADEMARK OFF. SOC’Y 62, 63
(2005).
5 Thomas P. Noud, Mark S. Carlson & Paul T. Meiklejohn, Patent Law Issues Affected by the
Predictability of Technology in the Field of Invention, 88 J. PAT. & TRADEMARK OFF. SOC’Y 603, 605
(2006); Brian P. O’Shaughnessy, The False Inventive Genus: Developing a New Approach for
Analyzing the Sufficiency of Patent Disclosure Within the Unpredictable Arts, 7 FORDHAM INTELL.
PROP. MEDIA & ENT. L.J. 147, 150–51 (1996).
6 See generally ROBERT C. FABER, LANDIS ON MECHANICS OF PATENT CLAIM DRAFTING
(Practising Law Institute 5th ed. 2005); Tom Brody, Functional Elements Can Ensure Allowance of
Genus Claims, 90 J. PAT. & TRADEMARK OFF. SOC’Y 621, 623 (2008) [hereinafter Brody, Allowance of
Genus Claims]; Tom Brody, Negative Claim Limitations in Patent Claims, 41 AIPLA Q.J. 29, 31
(2013) [hereinafter Brody, Negative Claim Limitations].
7 Tom Brody, Duty to Disclose: Dayco Products v. Total Containment, 7 J. MARSHALL REV.
INTELL. PROP. L. 325, 325 (2008) [hereinafter Brody, Duty to Disclose]; see also Dayco Prods., Inc. v.
Total Containment, Inc., 329 F.3d 1358, 1364 (2003) (noting that “the extent, if any, to which the
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claim construction,9 and claim construction’s role in infringement analysis.10 To
obtain a patent, one must also overcome common rejections in the form of
anticipation under 35 U.S.C. § 102,11 obviousness under 35 U.S.C. § 103,12 and nonenablement under 35 U.S.C. § 112.13 An introduction to patent law, suitable for
scientists and engineers, has been published. 14
This article concerns functional elements in patent claims. Claims include
structural elements, such as, hinge, spring, stent, photocell, steroid, and polypeptide,
as well as functional elements. In claims, the terms “configured for,” “capable of,” and
“adapted to,” are always followed by a functional element. In general, the Board
construes functional elements that use the phrase “capable of” in exactly the same
way that the Board construes functional elements that use the phrase, “adapted to”
or “configured for.” In one published opinion from the Federal Circuit, the court has

Patent Office rulemaking was intended to provide guidance to the courts concerning the duty of
disclosure in the context of inequitable conduct determinations is not clear”); Ferring B.V. v. Barr
Labs., Inc., 437 F.3d 1181, 1187 n.6 (Fed. Cir. 2006) (noting that both standards for the duty to
disclose were valid).
8 Douglas N. Modlin & Michael A. Glenn, International Patent Strategies for Individual
Inventors, 6 J. HIGH TECH. L. 129, 129 (2006).
9 The Federal Circuit frequently uses the “contexts of implication as a tool for claim
construction,” which is problematic because “they are usually inadvertent and not drafted into the
patent’s specification with the goal of narrowing claim scope.” Tom Brody, Claim Construction
Using Contexts of Implication, 13 VA. J.L. & TECH. 3, at *2, *57 (2008) [hereinafter Brody, Contexts
of Implication]; see also 35 U.S.C. § 112(a)–(b) (2012); Bell Atlantic Network Servs. v. Covad
Commc’ns Grp., Inc., 262 F.3d 1258, 1268 (Fed. Cir. 2001) (noting that “the specification may define
claim terms ‘by implication’ such that the meaning may be ‘found in or ascertained by a reading of
the patent documents’”) (quoting Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582, 1584 n.6
(1996)).
10 Tom Brody, Preferred Embodiments in Patents, 9 J. MARSHALL REV. INTELL. PROP. L. 398,
398–99 (2010) [hereinafter Brody, Preferred Embodiments]; see also Markman v. Westview
Instruments, Inc., 52 F.3d 967, 976 (1995) (“An infringement analysis entails two steps” where the
first is to determine the scope of the claim and the second is a comparison between “the properly
construed claims” and “the device accused of infringing”); Brody, Contexts of Implication, supra note
9 Table 2 (illustrating the two step analysis and how the Federal Circuit has applied it).
11 35 U.S.C. § 102(a) (“A person shall be entitled to a patent unless—the claimed invention was
described in a printed publication, or in public use, on sale, or otherwise available to the public
before the effective filing date of the claimed invention.”).
12 35 U.S.C. § 103. It states:
A patent for a claimed invention may not be obtained . . . if the differences
between the claimed invention and the prior art are such that the claimed
invention as a whole would have been obvious before the effective filing date of
the claimed invention to a person having ordinary skill in the art to which the
claimed invention pertains.
Id.; see also Tom Brody, Obviousness in Patents Following the U.S. Supreme Court’s Decision of KSR
International Co. v. Teleflex, Inc., 92 J. PAT. & TRADEMARK OFF. SOC’Y 26, 26–27 (2010) [hereinafter
Brody, Obviousness in Patents].
13 35 U.S.C. § 112 (“The specification shall . . . enable any person skilled in the art to which it
pertains, or with which it is most nearly connected, to make and use the same . . . .”); see also MPEP,
supra note 2, § 706.03(c).
14 TOM BRODY, CLINICAL TRIALS : STUDY DESIGN, ENDPOINTS AND BIOMARKERS, DRUG SAFETY,
AND FDA AND ICH GUIDELINES 607–23 (Academic Press 2012).
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construed functional elements reciting “capable of” and reciting “adapted for” in
different ways, as indicated by the footnote.15
Where a structural element is associated with a functional element, the
functional element limits the claim to structures that are capable of performing that
function.16 In other words, the functional element represents a laboratory test,
where the test screens for potential structures or candidate structures that satisfy
the recited function. This is also the first published in-depth article on functional
elements, aside from the author’s earlier article on this same topic.17
A. The nature of the problem.
The most common elements in patent claims are listed below:


Structural elements;



Functional elements;



Preamble;



Means plus function elements;



Negative limitations; and



Markush groups.

A claim that contains only a structural element can be found in U.S. Pat. No.
3,156,523 issued to Seaborg.18 The claim, which contains only one structural
element, reads:
“[Claim] 1. Element 95.”19
In contrast, an example of a claim to a structure, where most of the claim
language takes the form of functional elements, can be found in countless patents.

15 Aspex Eyewear, Inc. v. Marchon Eyewear, Inc., 672 F.3d 1335, 1349 (Fed. Cir. 2012). In
dicta, which at least in part, narrowly tracked the facts of the case, the Federal Circuit has
suggested that “capable of” language means something different from “adapted to” language. Id.
“Capable of” has a broader scope, while “adapted to” is narrower, where “adapted to” is defined as
follows. Id. According to the court, “adapted to” encompasses “capable of” and additionally
“designed to.” Id. Where a claim recites that a structure is “capable of” a particular function, the
phrase “capable of” encompasses structures that are capable of the function during the course of a
use that is intended by the patent, as well as structures that are capable of accomplishing tasks
through misuse or incidental use. Id. In contrast, “adapted to” encompasses only structures that
are capable of the use that is set forth in the patent. Id.
16 MPEP, supra note 2, § 2173.05(g).
17 See generally Brody, Allowance of Genus Claims, supra note 6.
18 U.S. Patent No. 3,156,523 col.1 (filed Aug. 23, 1946).
19 Id. col.11 l.24.
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One example is U.S. Pat. No. 6,170,651, issued to Taormina.20 One of the functional
elements in Claim 1 reads, “suitable for receiving in inserting fashion the pair of
eyeglasses.”21 Another of the functional elements in the same claim reads, “which is
actuated from a closed position to an open position in order to reveal an interior of
said shell and to permit the insertion or removal of the pair of eyeglasses.” 22
The convoluted nature of these particular functional elements hints at the
complex task of construing any claim that contains a functional element. What is
convoluted is that functional elements are found nested within functional elements.
The function indicated by “in order to” is nested within the function “which is
actuated.”23 Moreover, at first glance the meaning of the phrases, “suitable for” and
“in order to,” might strike one as being somewhat cryptic. This author points out
that “suitable for” and “in order to” are alternative versions of the more frequently
used phrase, “capable of.”
The main problem in construing functional elements is as follows. Cases from
the Federal Circuit are somewhat lacking in guidance for construing functional
elements. The author reviewed all cases from the Federal Circuit that contain the
terms “functional element,” “functional limitation,” and “functional language.” Most
of these concerned means plus function elements, and hence are not relevant to the
construction of functional elements. 24 Many of these cases merely referred to the
existence of a functional element in the disputed claim, again failing to provide
guidance on claim construction.25
Texas Instruments Inc. v. United States
International Trade Commission, a case from the Federal Circuit, cited a forty-five
year old opinion from the Court of Customs and Patent Appeals (“CCPA”), holding
that a functional element, “adds nothing to the patentability or substance of the
claim.”26 The Federal Circuit consequently refused to give patentable weight to a
functional element.27 But this type of logic is not consistent with the logic that is
used by essentially all cases from the Board. The CCPA, the predecessor of the
Federal Circuit, provides the following robust statement that functional elements do
have patentable weight, referring to the functional elements by a term that is usually
meant as a derisive term (“intended use”). In re Benson stated that:
Sometimes, as here, a material is as well defined by its intended use as by
its dimensions or other physical characteristics, and in this case we know of
U.S. Patent No. 6,170,651 (filed Dec. 17, 1999).
Id. col.7 l.27–28.
22 Id. col.7 l.31–34.
23 Id. col.7 l.31–32.
24 See Welker Bearing Co. v. PHD, Inc., 550 F.3d 1090, 1095 (Fed. Cir. 2008); LG Elecs., Inc. v.
Bizcom Elecs., Inc., 453 F.3d 1364, 1372 (Fed. Cir. 2006); Linear Tech. Corp. v. Impala Linear Corp.,
379 F.3d 1311, 1319–20 (Fed. Cir. 2004); Asyst Techs., Inc. v. Empak, Inc., 268 F.3d 1364, 1369–70
(Fed. Cir. 2001); Chiuminatta Concrete Concepts, Inc. v. Cardinal Indus., Inc., 145 F.3d 1303, 1309
(Fed. Cir. 1998).
25 See Freedman Seating Co. v. Am. Seating Co., 420 F.3d 1350, 1362 (Fed. Cir. 2005); Zodiac
Pool Care Inc. v. Hoffinger Indus., Inc., 206 F.3d 1408, 1416 (Fed. Cir. 2000); Ethicon Endo-Surgery,
Inc. v. U.S. Surgical Corp., 93 F.3d 1572, 1577 (Fed. Cir. 1996); Insta-Foam Prods., Inc. v. Universal
Foam Sys., Inc., 906 F.2d 698, 701 (Fed. Cir. 1990).
26 Tex. Instruments Inc. v. ITC, 988 F.2d 1165, 1172 (Fed. Cir. 1993) (citing Israel v. Cresswell,
166 F.2d 153, 156 (C.C.P.A. 1948)).
27 Id.
20
21
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no reason why the limitation in terms of use should not be placed in the
claims and given meaning in their interpretation.28
The Federal Circuit adopted the cases from the CCPA as precedent. 29
B. The nature of the solution.
This article mainly concerns cases from the Patent Trial and Appeal Board
(“PTAB”), formerly known as the Board of Patent Appeals and Interferences
(“BPAI”). At most, about six cases from the Federal Circuit provide any guidance on
functional elements, and these cases are documented herein. In the context of civil
procedure, nearly all of the cases heard by the Board are appeals from an examiner’s
final rejection. Cases from the Board constitute a huge body of applied case law that
provides guidance on many more issues in claim construction than will ever be found
in cases from the Federal Circuit. Accounts of the history of the Board are found in
the cited references.30 About 600 cases from the Board concern functional elements.
In reviewing all of these cases, the author discovered about a dozen distinct issues—
that is, a dozen distinct themes—in construing functional elements.
C. Example of a claim with a functional element.
The following opinion concerned a claim possessing a functional element, where
the wording in the claim dramatically establishes the connection between the
function and a laboratory test. The footnote illustrates patents where a functional
element in the claim was correlated with a laboratory test. 31 Most claims that
Application of Benson, 418 F.2d 1251, 1254 (C.C.P.A. 1969).
STEVEN FLANDERS, THE FEDERAL CIRCUIT—A JUDICIAL INNOVATION, ESTABLISHING A U.S.
COURT OF APPEALS 38–39 (Twelve Tables Press 2010); South Corp. v. U.S., 690 F.2d 1368, 1369
(Fed. Cir. 1982) (“We hold that the holdings of our predecessor courts, the United States Court of
Claims and the United States Court of Customs and Patent Appeals . . . shall be binding as
precedent in this court.”).
30 See generally Paul J. Federico, The Board of Appeals 1861–1961, 43 J. PAT. & TRADEMARK
OFF. SOC’Y 691, 691 (1961); Paul J. Federico, Evolution of Patent Office Appeals, 22 J. PAT. &
TRADEMARK OFF. SOC’Y 838, 838 (1940); Jeffrey W. Rennecker, Ex Parte Appellate Procedure in the
Patent Office and the Federal Circuit’s Respective Standards of Review, 4 TEX. INTELL. PROP. L.J.
335, 340 (1996); Alan L. Koller, The Role of the Patent Commissioner in Designating Panels from the
Board of Patent Appeals and Interferences, 34 IDEA 185, 187 (1994).
31 Claims to devices or to compositions of matter, where the claim includes a functional
element, and where the functional element is further confined or restricted by the identification of a
screening test, can be found in the following patents. U.S. Pat. No. 7,812,214 issued to Koele, et al,
requires use of the ASTM-E132 test. See U.S. Patent No. 7,812,214 col. 11 l. 38–40 (filed Feb. 28,
2006). U.S. Pat. Nos. 8,021,664 issued to Berinstein, and 7,842,294 issued to Andersen, require use
of the ELISPOT test. See U.S. Patent No. 8,021,664 col. 77 l. 45 (filed Apr. 15, 2004); U.S. Patent
No. 7,842,294 col. 63 l. 3 (filed Nov. 18, 2004). U.S. Pat. No. 4,075,131 claims a shampoo, where the
claim contains a functional element, and where the functional element requires that the function
(viscosity) of the shampoo be tested with a specific machine, a viscometer. See U.S. Patent No.
4,075,131 col. 10 l. 41–50 (filed Sept. 17, 1976). Ex parte Ahrens discloses a functional element that
represents a laboratory test. Ex parte Ahrens, No. 2008-3812, 2008 WL 4266207, at *1, *3 (B.P.A.I.
28
29
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possess a functional element do not also identify a laboratory test. However, it is
important that the specification contain a sentence or two that describes a laboratory
test that corresponds to each of the functional elements in the claim set. On
occasion, during the prosecution phase of a patent application, the examiner requires
that wording describing the test be added, by way of amendment, to the claim.
The following provides a model example of a claim with a functional element.
The claim is a model example, because the functional element contains a disclosure of
a laboratory test. Although functional elements that actually describe a laboratory
test are uncommon, it should be kept in mind that all functional elements in all
patents refer to functions that can be tested, verified, or compared, by way of a
laboratory test.
Ex parte Kao concerned the following claim.32 The functional element is shown
in bold. The associated structure is “tablet.” The functional element requires that
the tablet possess the function of dissolving at the indicated rate. The rate is 15–50%
over the course of an hour.
[Claim] 1. An analgesically effective . . . pharmaceutical composition . . . in
the form of a tablet, comprising oxymorphone or a pharmaceutically
acceptable salt thereof . . . wherein upon placement of the composition
in an in vitro dissolution test comprising USP Paddle Method at 50
rpm in 500 ml media having a pH of 1.2 to 6.8 at 37 ºC, about 15% to
about 50%, by weight, of the oxymorphone . . . is released from the
table at about 1 hour in the test.33
The test requires that the composition be capable of dissolving at a specific rate
when placed in a medium of pH 1.2–6.8.
In drafting claims that include a functional element, the attorney or agent
should consider including, in the specification, a short description of a laboratory test
that can screen devices for the ability (or inability) to perform that function. The
disclosure of this test can be useful when the attorney needs to draft a rebuttal
against a rejection that alleges non-enablement, or when the attorney needs to draft
a rebuttal against a rejection that alleges invalidity under 35 U.S.C. § 102 or 35
U.S.C. § 103. For rebutting a rejection that alleges invalidity, the rebuttal should
provide a reasoned argument why the cited prior art flunks the laboratory test—that
is, why the cited prior art does not possess the function.
Where a functional element includes a short description of a laboratory test, and
where this description includes various devices or instruments, it must be recognized
that the names of these devices and instruments do not have any patentable weight.
This issue of structural terms residing within a functional element, which is a

Sept. 16, 2008). The Board construed the functional element “capable of initiating transcription in a
plant cell,” and characterized it as a test, writing that, “it was routine in the art as of the application
filing date to make and test promoter fragments and sequence variants for activity.” Id. (emphasis
omitted). The activity was that of initiating transcription in a plant cell. Id. at *1.
32 Ex parte Kao, No. 2009-013710, 2010 WL 200411, at *1 (B.P.A.I. Jan. 12, 2010).
33 Id.
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potential trap, is detailed below in commentary on Ex parte Hough and Ex parte
Hovath.34
II. METHODOLOGY
In June 2011, the author inputted various search terms for exploring opinions
from the Board, using the search device at www.uspto.gov. These search terms
included “Swinehart” in combination with, for example, “functional limitation,”
“functional element,” and “functional language,” as well as more targeted searches,
using combinations of terms such as: (1) “assay method” AND “functional,” (2) “ex
parte levy” AND “functional,” (3) “ex parte levy” AND “functionally,” (4)
“indefiniteness” AND “functional element,” (5) “indefiniteness” AND “functional
limitation” and “intended use.” In October 2011, the author conducted another large
search, specifically targeted to all existing cases citing In re Oelrich, In re Rijckaert,
or Ex parte Levy, or citing the forty most recent cases citing In re Swinehart (but not
citing Oelrich, Rijckaert, or Levy). In November 2011, the author considered the
possibility that bias could result from using a case name as a query term, and thus
conducted three more searches inputting “functional element,” 35 “functional
language,”36 “functional limitation,”37 and “functionally claimed”38 as the query term,
but without imputing a case name. In November 2012, the author conducted
additional searches of the Board’s most recent opinions. To acquire opinions from the
Federal Circuit, the author used LexisNexis® at Boalt Hall at the University of
California at Berkeley. In January 2013, the author conducted an additional search
of cases from the Board (dating from Jan. 1, 2012 to Dec. 31, 2012), using the query
term “inherency,” reviewed all 329 cases, and detected fifteen more relevant cases, all
of which are cited herein.
III. PHYSICAL NATURE OF FUNCTIONAL ELEMENTS, IN THE CONTEXT OF A CLAIM.
A. Subsets of functional elements that dictate structure.
Functional elements can confer two types of structure to the structural elements
in the claim. The first type of structure is the shape, dimension, or chemical
composition of a particular structural element. The second type of structure is the
arrangements in space between two or more structural elements that are recited in
the claim.
Geneva Pharmaceuticals, Inc. v. GlaxoSmithKline PLC 39 and R.A.C.C.
Industries, Inc. v. Stun-Tech, Inc.40 set forth the proper role of functional elements in
See infra Part VIII.F.
The author reviewed all 40 of the hits.
36 The author reviewed the first 180 consecutive hits out of 566 hits.
37 The author reviewed the first 240 consecutive hits out of 1292 hits.
38 The author reviewed all twelve cases.
39 Geneva Pharm., Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373, 1384 (Fed. Cir. 2003).
34
35
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claims. These cases provide the following rules. First, it is the case that, “functional
[language] covers all embodiments performing the recited function.” 41 Second, it is
the case in anticipation analysis that “[f]unctional language in an apparatus claim
requires that an accused apparatus possess the capability of performing the recited
function.”42
According to the Manual of Patent Examining and Procedure (“MPEP”), “[a]
functional limitation is often used in association with an element, ingredient, or step
of a process to define a particular capability or purpose that is served by the recited
element, ingredient or step.”43 Thus, where a claim encompasses several variations
of one device or of one composition, and where the claim includes a functional
element, it is the case that the claim covers only those devices or compositions that
exhibit the function that is recited by the functional element. The functional element
serves as a screening assay.
The following concerns functional elements that dictate relationships between
different structural elements. In Innova/Pure Water Inc. v. Safari Water Filtration
Sys. Inc., the court noted that the functional element, “operatively connected” is “a
general descriptive [claim] term frequently used in patent drafting to reflect a
functional relationship between claimed components,” that is, the term “means the
claimed components must be connected in a way to perform a designated function.” 44
1. Functional element that dictates the shape, dimension, or chemical composition of a
particular structural element.
Claim construction of a claim with a functional element can be completed by
determining if the recited function compels a particular structure for the claimed
device. For example, in Ex parte Ignatiev, the Board wrote that proper claim
construction involves asking “whether the functional language structurally
distinguishes the claimed apparatus from the prior art apparatus.” 45 To give another
example, in Ex parte Adler, the claim was to a molecule having the function of
binding to chemicals with a bitter taste.46 The Board held the range of structures of
the claimed molecules—that is, the genus of molecules—was governed by “functional
characteristics when coupled with a known or disclosed correlation between function
and structure.”47 In Ex parte Abad, the claim was to a nucleic acid having a
pesticidal function.48 The functional element in the claim was, “which is pesticidal

40 R.A.C.C. Indus., Inc. v. Stun-Tech, Inc., No. 98-1186, 1998 U.S. App. LEXIS 30769, at *9
(Fed. Cir. Dec. 2, 1998).
41 Geneva Pharm., 349 F.3d at 1384.
42 R.A.C.C., 1998 U.S. App. LEXIS 30769, at *9 (citing Intel Corp. v. U.S. Int’l Trade Comm’n,
946 F.2d 821, 832 (Fed. Cir. 1991)).
43 MPEP, supra note 2, § 2173.05(g).
44 Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1118 (Fed. Cir.
2004).
45 Ex parte Ignatiev, No. 2009-011747, 2010 WL 1188327, at *4 (B.P.A.I. Mar. 25, 2010).
46 Ex parte Adler, No. 2006-0157, at *3 (B.P.A.I. Mar. 23, 2006).
47 Id. at *7.
48 Ex parte Abad, No. 2007-4213, 2008 WL 904456, at *1 (B.P.A.I. Apr. 3, 2008).
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for at least one pest.”49 The Abad opinion teaches that claim construction can involve
a determination of which variations (which species) of the claimed nucleic acid
possesses the function that is required by the functional element. The Abad opinion
expressly stated that the functional element “defined” the claimed molecule. 50 The
Board wrote that “Claim 1 is directed to a nucleic acid defined by [the following]
properties . . . [including having] pesticidal activity towards a pest.”51
The following provides another example. Ex parte Takahashi stated that the
recitation of “intended use”—that is, the recitation of the functional element—can
lend patentable weight to a claim, where the appropriate approach to claim
construction is to determine if the prior art apparatus is capable of performing the
intended use.52 In other words, if the prior art cannot perform the intended use, the
claim element has prevented the prior art from invalidating the claim. The Board’s
words express the general approach to claim construction. The Board wrote that “the
prior art structure meets the claims because the prior art apparatus is capable of
performing the intended use.”53
Ex parte Johnson concerns the functional element highlighted below:
“a composition comprising . . . a zinc containing material having an
aqueous solubility . . . of less than about 25% by weight.”54
The associated structure is “zinc containing material.” In construing the claim,
the Board reviewed the specification, and observed definitions, examples, and the
disclosure of a screening assay that tests aqueous solubility. 55 The screening assay
determines the solubility of any given species, and those that give a positive test
result are covered by the claims. 56 Where a species gives a negative result with the
screening assay, that particular species is not covered by the claim. 57 In view of the
definitions, examples, and screening assay, the Board in Ex parte Johnson, supra,
reversed the rejections for lack of written description and for non-enablement, and
held the claim to be valid.58
2. Functional element that dictates an arrangement of structural elements.
One subset of functional element is one that dictates the positioning of various
structural elements with respect to each other. This subset of functional elements is
set forth by Ex parte Flowers.59 In this opinion, the claim contained an element that

Id.
Id. at *10.
51 Id.
52 Ex parte Takahashi, No. 2004-2192, 2004 WL 2733658, at *2 (B.P.A.I. Sept. 30, 2004).
53 Id.
54 Ex parte Johnson, No. 2009-006686, 2009 WL 5455504, at *1 (B.P.A.I. Dec. 30, 2009).
55 Id. at *2–3.
56 Id. at *2.
57 Id.
58 Id. at *8.
59 Ex parte Flowers, No. 2008-1069, 2008 WL 503577, at *5 (B.P.A.I. Feb. 21, 2008).
49
50
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confers spatial arrangements of the claimed structural elements. 60 In characterizing
the functional element, the Board wrote, “[w]e construe this clause to set forth
spatial limitations on the alignment structure relative to the front lip of the tub in
functional terms.”61 This special subset of functional element was also used in Ex
parte Paul, where the functional element, “in contact with,” determines an
arrangement of structures.62 Similarly, in Ex parte Kanflod, the issue was a
functional element that described a particular arrangement that allows cooperation
between structural elements.63 Ex parte Flowers, Ex parte Paul, and Ex parte
Kanflod disclose that functional elements impose requirements on claimed
structures, but can also mandate an arrangement between the structures described
by the functional element in the claim. These three cases provide the attorney with a
powerful claim-drafting tool.
IV. THE PRACTICAL UTILITY OF FUNCTIONAL ELEMENTS.
Functional elements in claims fall into various categories and serve various
uses. These categories include:
Taking the place of a structural element, thereby enhancing claim
breadth;64
Taking the place of a structural element where the structure is unknown or
cannot be defined by the inventors;65
Distinguishing the claimed invention from the prior art, thereby defending
the claim from rejections for anticipation (35 USC § 102) or for obviousness
(35 USC § 103);66 and
Confining the scope of a structural element that is a broad genus, thereby
ensuring compliance with the requirement for enablement under 35 USC
§ 112. Functional elements are routinely used in biotechnology claims. 67
Id.
Id.
62 Ex parte Paul, No. 2007-3404, 2008 WL 552676, at *1 (B.P.A.I. Feb. 29, 2008).
63 Ex parte Kanflod, No. 2009-006604, 2010 WL 3032866, at *1 (Aug. 2, 2010).
64 Brody, Allowance of Genus Claims, supra note 6, at 623.
65 Personal communication with Mark Lemley, William H. Neukom Professor of Law at
Stanford Law School, at Improving the Interface Between the USPTO and the Federal District
Courts, USPTO & Berkeley Center for Law & Technology, Bancroft Hotel, Berkeley, CA (June 7,
2011). Professor Lemley stated:
60
61

You might do it because you can’t define the invention any other way, so the chemical
product by process claims fit into this category. . . . It’s [functional elements]—not quite
the same thing [as product by process claims], but it seems to me to be analogous. . . . I
have an antigen that I can’t characterize except by what it binds to.
Id.
66

Brody, Allowance of Genus Claims, supra note 6, at 623.
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The following discloses a spectrum of favorable to unfavorable aspects of
functional elements.
The following bullet points and narratives outline the
advantages and disadvantages of using functional elements in claim drafting.


Advantage. Enabling broader claim scope. This advantage is
documented by the following statement in Ex parte Kolarov: “This
functional limitation renders the claim quite broad, and covers
essentially any embodiments that perform the recited function of
matching a capacity of a communication network.” 68



Advantage.
Taking the place of structural language, where
structural descriptions are not possible.69



Advantage. Facilitate communication with jury.70



Advantage.
Adding difficulty to prior art searches that are
conducted by an adverse party.
On the other hand, the
corresponding disadvantage is that when an attorney is
contemplating filing a patent application, but first intends to
conduct a prior art search, the presence of functional elements in
the prior art can encumber the attorney’s prior art search.71



Disadvantage.
After filing the patent application, use of a
functional element can have the disadvantage of a consequent
increase in prior art rejections based on citations from technologies
that are remote to the claims. This fact-pattern is detailed below
under the heading, “A. Worst-case scenario.”72



Disadvantage. The attorney or agent might be tempted to use a
functional element that is so broad and indistinct, that the
functional element fails to confine the associated structural element
to any particular dimension or substance. Ex parte Edlund provides
an example of this disadvantage. 73 A more detailed example of this

Id. at 653.
Ex parte Kolarov, No. 2009-005070, 2010 WL 1252103, at *5 (B.P.A.I. Mar. 30, 2010).
69 Brody, Allowance of Genus Claims, supra note 6, at 623.
70 Personal communication with Bruce McCubbrey, Counsel at Manatt, Phelps & Phillips,
LLP, at Improving the Interface Between the USPTO and the Federal District Courts, USPTO &
Berkeley Center for Law & Technology, Bancroft Hotel, Berkeley, CA (June 7, 2011) [hereinafter
Personal communication with McCubbrey].
71 This observation is based on the author’s thirteen years of experience in prior art searches
and invalidity analysis.
72 See infra Part V.A.
73 Ex parte Edlund, No. 2009-014696, 2010 WL 4991390, at *4–5 (B.P.A.I. Dec. 5, 2010).
Regarding the failure of the functional elements to confer any particular shape, dimension, or
composition, to the structural elements in the claim, the opinion stated:
67
68

Edlund has not claimed a process, or even an apparatus that positively recites the
presence of certain materials that are conveyed to various parts of the apparatus. . . . In
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disadvantage is shown below, under the heading, “B. Worst-case
scenario.”74


Disadvantage. The attorney or agent might draft a functional
element but neglect to associate it with a bona fide structural
element. For example, the functional element might be associated
with a word that does not mandate any structure, such as the word,
“member,” “device,” “element,” “component,” “mechanism,” or
“structure.” The result is that the claim can be rendered invalid.75

Functional elements in claims are good, in that they can take the place of
structural language, where it is impossible or difficult to use structural language.
Functional elements are also good, in that they usually enable claim drafting that
encompasses a broader range of structures than a corresponding structural element,
thereby leading to broader claim scope.
Functional elements might be preferred in the early stages of any particular
technology, where there will not likely be any existing prior art structures that can
perform the same function, while structural elements might be preferred in latestage technologies, where the field is crowded with patented inventions.
Regarding the goal of enhancing communication with a jury, functional elements
in claims can prevent the claim from resembling the traditional song, Dem Bones,
thereby making the claim easier for the jury to understand. 76 Dem Bones contains
the lyrics, “The leg bone connected to your knee bone/The knee bone connected to
your thigh bone/The thigh bone connected to your hip bone.”77 This rationale for
using functional elements finds a basis in the case law, as articulated in the MPEP:
“a claim which fails to interrelate essential elements of the invention as defined by
applicant(s) in the specification may be rejected under 35 U.S.C. 112, second
paragraph, for failure to point out and distinctly claim the invention.” 78
Thus, where a device contains two or more structures, a functional element can
be used to disclose a relation between the two structures.

the present claims, however, Edlund seeks to use the term “adapted to” to define
structures solely by their function within the claimed apparatus.
Id.

See infra Part V.B.
Halliburton Oil Well Cementing Co. v. Walker, 329 U.S. 1, 14 (1946), cited in Ex parte
Eidson, No. 2007-1098, 2007 WL 1787646, at *3 (B.P.A.I. June 20, 2007). Ex parte Harvey identifies
elements that are purely functional as a distinct class of claim elements, stating that, “[t]his type of
purely functional claiming where the statement of function is not attached to any structure or act, or
to any ‘means’ or ‘step,’ is not permitted.” Ex parte Harvey, No. 2007-2115, at *46 (B.P.A.I. Jan. 13,
2009); see also Ex parte Merdan, No. 2010-009279, 2010 WL 3454262, at *2 (B.P.A.I. Aug. 31, 2010).
76 Personal communication with McCubbrey, supra note 70; Mark Czerniec, Ezekiel and Dry
Bones: The Bone Song (‘Dem Bones Dem Bones’), MARKCZ.COM (Oct. 19, 2011, 1:25 P.M.),
http://markcz.com/bone-song/.
77 Czerniec, supra note 76. Lyrics based on Ezekiel 37:1-10. Id.
78 MPEP, supra note 2, § 2172.01.
74
75
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V. EXAMPLES OF PATENT PRSOECUTION THAT INVOLVE REJECTIONS AGAINST A CLAIM,
WHERE THE REJECTION WAS DIRECTED AGAINST A FUNCTIONAL ELEMENT.
The following examples illustrate the prosecution of claims having a functional
element, and illustrate a typical scenario of a rejection, as well as selected worst-case
scenarios involved in patent prosecution.
The following illustrates the typical type of prior art that is cited against a
claim—that is, prior art that resides in the same technical field as the claim. This is
not a worst-case scenario, but this example provides a context for understanding the
worst-case scenarios that are subsequently disclosed below.
In Ex parte Glidewell, the prior art device and the claimed device were both
fishing tackle boxes.79 Claim 1 contained the following recitation. The associated
structure is “slot”:
said vertical plane defining a slot adapted to removably hang hooks of
artificial bait.80
Thus, the invalidity question was whether the cited prior art (Bruce) disclosed a
slot that could perform this same function. 81 Bruce disclosed a fishing tackle box
with slots.82 Even though Bruce did not disclose anything about removably hanging
hooks of artificial bait, the Board held that Bruce was still capable of performing the
function, and rejected the claim. 83 In other words, Bruce did not expressly disclose
the functional element. Instead, Bruce inherently disclosed the functional element.
The above is the usual scenario, when an examiner or the Board studies a prior
art reference, and seeks an express disclosure or an inherent disclosure of a
functional element.
A. Worst-case scenario, relating to invalidation by prior art.
The author refers to the following examples as “worst-case scenarios,” because it
is difficult for an inventor to rebut the allegation that the prior art is capable of the
same function as a function of the claimed invention. This is a worst-case scenario
because the attorney or agent is not likely to detect this reference by way of a prior
search—that is, a prior art search conducted before filing the patent application.
1. The inventor fruitlessly argued that a hair clip is not a medical clamp.
When an attorney chooses to use a functional element it invites the following
worst-case scenario. The examiner may find a prior art device that is in a field
79 Ex parte Glidewell & Horton, Jr., No. 2008-5112, 2008 WL 5228902, at *1, *2 (B.P.A.I. Dec.
12, 2008).
80 Id. at *1.
81 Id. at *2.
82 Id.
83 Id. at *6.
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totally afield from the claimed invention, but where the prior art device is capable of
the very same function as that recited in the functional element. Ex parte Ortiz
provides an example.84 The claim concerned a medical device.85 The associated
structure is “clamp body”:
[Claim] 13. A clamp for gastric reduction surgery, comprising: a clamp
body shaped and dimensioned to create a gastric pouch.86
The examiner’s job prima facie task is to find prior art that possesses structural
elements that correspond to the structural elements of the claim.87 Also, in the
situation where the claim contains a functional element, the examiner’s prima facie
task is to find structural elements in the prior art that possess the same function. 88
Thus, in Ex parte Ortiz, the examiner cited the Shyu prior art (U.S. Patent No.
D473,342),89 which disclosed a hair clip (see Figure 1). The inventor fruitlessly
argued that the hair clip was not intended for use in the stomach. 90 Referring to the
inventor’s fruitless argument, the opinion stated that “Appellants’ sole contention
regarding the Examiner’s rejection of claim 13 as being anticipated by Shyu is that
no one in the medical profession would attempt to use a hair clip during a surgical
procedure.”91 But the examiner argued, and the Board agreed, that “placement of
this hairclip in the stomach could form a pouch,” as required by the claims. 92 The
Board affirmed the rejection.93 Thus, one risky and dangerous aspect of using a
functional element in a claim, is that the inventor will not likely be aware of devices
in a field that is totally unrelated to her invention, and will not have performed any
kind of prior art search of that remote field before drafting the claims, and
submitting the patent application.

Ex parte Ortiz, No. 2009-012288, 2011 WL 2513948, at *2 (B.P.A.I. June 22, 2011).
Id. at *1.
86 Id.
87 37 C.F.R. § 1.104(c)(2) (2013).
88 Ortiz, 2011 WL 2513948, at *2.
89 Id. at *1, *2.
90 Id. at *2.
91 Id.
92 Examiner’s Answer, U.S. Patent Application No. 11/197,528, at 7 (Apr. 16, 2009).
93 Ortiz, 2011 WL 2513948, at *2.
84
85
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Figure 1.

2. The inventor fruitlessly argued that a dishwashing pad is not a medical device for
constraining the heart.
The same type of worst-case scenario occurred in Ex parte Alferness, which
concerned a cardiovascular medical device, where the device was a jacket for
constraining the heart.94
The claim contained functional language.95
Unfortunately for the inventor, the examiner found a patent dating from 1928 (U.S.
Pat. No. 1,682,119), which disclosed a jacket for holding soap chips.96 This device
was the well-known Brillo® pad.97 Both the cardiovascular jacket and the Brillo pad
were capable of performing the same function. The result is that the claim was
rendered invalid in view of the cited prior art. 98
To reiterate, a danger of using a functional element instead of an appropriate
structural element is that the examiner may find a device in a remote technology
that is capable of performing the same function. Where the examiner finds a device
Ex parte Alferness, No. 2008-4555, 2009 WL 180335, at *1 (B.P.A.I. Jan. 23, 2009).
Id. at *1, *5.
96 Id.; see also U.S. Patent No. 1,682,119 at 1, l.1–7 (filed Oct. 8, 1925).
97 ‘119 Patent, at 1, l.1–7.
98 Alferness, 2009 WL 180335, at *9.
94
95
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that is capable of performing the same function, the prior art device can render the
claim invalid.
A similar type of unexpected backfiring of an attempt to use functional elements
is shown in Ex parte Meyer.99 In this opinion, the claim was to a hand-held
massaging machine.100 The functional element was “wherein the user may grasp
the handle portion and apply the massage effect to a body part.”101 However, the
claim was invalidated by a prior art device that was a motorized wire brush.102
The inventor fruitlessly argued that a user would not use a motorized wire brush as a
massage device.103
The take-home lesson is that attorneys and agents should be aware that where a
claim to a structure relies extensively on functional language, it increases the risk
that the examiner will find invalidating prior art in technologies that are totally
remote from technology of the presently claimed invention.
B. Worst-case scenario, relating to rejections for lack of written description (35 U.S.C.
§ 112).
The following problem is likely to arise in the unpredictable arts—that is,
chemistry and biology—where the specification of a patent application identifies only
one or two species of the invention, but where the claim set encompasses a genus.
The advantage to the inventor of drafting this type of claim is that the genus claim
covers an open-ended number of pharmaceuticals, but the inventor only did enough
laboratory work to acquire complete information on the molecular structure of one
species. But the disadvantage is that if the function is too broad, the claim will be
rejected.
Ex parte Norin concerned the following claim.104 The associated structure is
“protein.”
[Claim] 1.
cells.”105

An isolated . . . protein . . . which binds natural killer

Thus, the inventor was attempting to create intellectual property that
encompassed an unlimited number of proteins by the technique of submitting a claim
that recited the function of this unlimited number of proteins. 106 The function was
that of binding to natural killer cells (NK cells). Killer cells are a type of cell in the
immune system.107 The Board rejected the claim for lack of written description,
writing that, “Appellant has not provided any identification of a single region or
Ex parte Meyer, No. 2009-002681, 2009 WL 2403810, at *2 (B.P.A.I. Aug. 4, 2009).
Id. at *1.
101 Id.
102 Id. at *2.
103 Id. at *3–4.
104 Ex parte Norin, No. 2009-010366, 2010 WL 2420454, at *1 (B.P.A.I. June 15, 2010).
105 Id.
106 Id. at *5–6.
107 TOM BRODY, CLINICAL TRIALS:
STUDY DESIGN, ENDPOINTS AND BIOMARKERS, DRUG
SAFETY, AND FDA AND ICH GUIDELINES 503–16 (Academic Press/Elsevier 2012).
99

100
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multiple regions within the p38.5 protein which are involved in NK binding,” citing
the on-point case, University of Rochester v. G.D. Searle & Co.108 The take-home
lesson of Ex parte Norin is relevant to the unpredictable sciences. The issues in Ex
parte Norin and in Rochester v. Searle rarely arise in cases relating to the predictable
arts, such as engineering.109
The take-home lesson is that attorneys and agents should use functional
elements with care and restraint when claim-drafting in the unpredictable arts.
Ex parte Waldmann is similar to Ex parte Norin, in that the claims also attempt
to cover an antibody.110 The claim was as follows. The associated structure is
“antibody”:
[Claim] 1. A pharmaceutical comprising . . . a therapeutic antibody that
binds to a therapeutic target, said antibody being modified with a
peptide that reduces binding of the antibody to the therapeutic
target.111
The Board rejected the claim for failing to satisfy the written description
requirement, writing:
Appellants’ argument reduces the invention to the solely functional
elements. . . . That is the central issue here, where only a single species of
antibody and peptide are disclosed, we conclude that Appellants’ claims
“merely recite a description of the problem to be solved while claiming all
solutions to it.”112
The Board cited Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.113 and
University of Rochester v. G.D. Searle and Co.114 The take-home lesson is that at
least in the unpredictable arts, functional elements can introduce an increased risk
for rejections under 35 U.S.C. § 112 for lack of written description.

108 Norin, 2010 WL 2420454, at *8; Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 925
(Fed. Cir. 2004).
109 See, e.g., Ex parte Rodriguez, No. 2008-000693, 2009 WL 3756279, at *23 (B.P.A.I. Oct. 1,
2009).
110 Ex parte Waldmann, No. 2011-003005, 2011 WL 2661226, at *1 (B.P.A.I. July 6, 2011). An
antibody is a protein that tightly and specifically binds to a target. Typically, the target is another
protein, where the protein can be free or where the target protein is attached to the outside of a
living cell. See, e.g., H. Metzger & J.P. Kinet, How Antibodies Work: Focus on Fc Receptors, 2 FED’N
AM. SOCIETIES FOR EXPERIMENTAL BIOLOGY J. 3, 3–11 (1988); Tom Brody, Multistep Denaturation
and Hierarchy of Disulfide Bond Cleavage of a Monocolonal Antibody, 247 ANALYTICAL
BIOCHEMISTRY 247, 247–56 (1997).
111 Waldmann, No. 2011-003005, 2011 WL 2661226, at *1 (B.P.A.I. July 6, 2011).
112 Id. at *6.
113 Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1353 (Fed. Cir. 2010).
114 Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 926 (Fed. Cir. 2004).
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C. Best Case Scenario
Where a claim is rejected in view of the prior art, and where it is alleged that the
prior art discloses all of the structural elements and also all of the functional
elements, the best-case scenario is when the inventor succeeds in arguing that the
prior art fails to disclose all of these elements. The cited cases are representative
examples of opinions where the inventor succeeded in persuading the Board that the
cited prior art failed to disclose the functional element. In arriving at a holding in
these particular opinions, the Board typically writes that the examiner “has failed to
provide sufficient evidence or scientific reasoning” that the cited prior art is capable
of performing the same function as the function possessed by the claimed device. 115
To provide a concrete example, in holding that the examiner had failed to meet the
prima facie burden regarding the prior art’s ability to perform a function required by
the claim, the Board wrote that, “the examiner has not even attempted much less
succeeded in establishing that Allred’s safety device [the prior art] is capable of being
attached to a ladder . . . in the manner required by the . . . claims.”116
VI. COMPOUND NOUNS.
Functional elements can take the form of a compound noun, where the
compound noun includes a structural element and a functional element. Compound
nouns117 that contain both a structural element and a functional element are common
in patent claims. Claim elements that are compound nouns are construed by
techniques used for construing typical functional elements. Compound nouns resist
invalidation by the prior art more than claim elements that are merely structural
115 Ex parte Becker, No. 2010-004730, 2012 WL 1424845, at *2 (B.P.A.I. Apr. 22, 2012); Ex
parte Christ, No. 2010-005928, 2012 WL 4483343, at *3 (B.P.A.I. Sept. 18, 2012); Ex parte
Ciancimino & Moreira, No. 2009-012280, 2012 WL 2513947, at *3 (B.P.A.I. June 21, 2011); Ex parte
Dewey, No. 2010-006525, 2011 WL 3666742, at *2–3 (B.P.A.I. Aug. 18, 2011); Ex parte Dronzek, Jr.,
No. 2010-001371, 2010 WL 4789644, at *2 (B.P.A.I. Nov. 23, 2010); Ex parte Eckhardt, No. 2011009019, 2012 WL 4955443, at *2 (B.P.A.I. Oct. 15, 2012); Ex parte Fischer, No. 2010-005516, 2012
WL 3903344, at *2 (B.P.A.I. Sept. 6, 2012); Ex parte Field & Pouliot, No. 2009-015300, 2011 WL
1341753, at *2 (Apr. 6, 2011); Ex parte Gottis, No. 2001-0008, 2002 WL 31234500, at *4 (B.P.A.I.
Jan. 16, 2002); Ex parte Grilliot & Grilliot, No. 2010-005532, 2012 WL 4483273, at *2 (B.P.A.I. Sept.
17, 2012); Ex parte Hagan, No. 2009-009157, 2011 WL 121765, at *4 (B.P.A.I. Jan. 12, 2011); Ex
parte He & Harwell, No. 2011-005552, 2011 WL 2693009, at *4 (B.P.A.I. July 5, 2011); Ex parte
Louw, No. 2010-006062, 2012 WL 2406017, at *4 (B.P.A.I. June 22, 2012); Ex parte McCarthy, No.
2009-013718, 2011 WL 2658869, at *3 (B.P.A.I. July 5, 2011); Ex parte McCrory, No. 2010-003076,
2012 WL 424124, at *3 (B.P.A.I. Feb. 8, 2012); Ex parte Paquette, No. 2010-010075, 2011 WL
1303798, at *4 (B.P.A.I. Apr. 4, 2011); Ex parte Rickerd, No. 2010-007223, 2012 WL 2486786, at *3
(B.P.A.I. June 27, 2012); Ex parte Siess & Penners, No. 2009-015015, 2011 WL 1661482, at *2
(B.P.A.I. Apr. 2, 2011); Ex parte Soika & Arich, No. 2010-002671, 2011 WL 4894095, at *2 (B.P.A.I.
Sept. 28, 2011); Ex parte Sommerfeld & Schadt III, No. 95-3734, 1995 WL 1693067, at *3 (B.P.A.I.
Aug. 24, 1998); Ex parte Spinelli & Rastegar, No. 2009-010380, 2011 WL 1631152, at *2 (B.P.A.I.
Apr. 26, 2011); Ex parte Streuer, No. 2009-013528, 2010 WL 4264565, at *3 (B.P.A.I. Oct. 28, 2010);
Ex parte Tonev, No. 2011-006444, 2012 WL 2165994, at *4 (B.P.A.I. June 12, 2012); Ex parte Zheng,
No. 2010-003543, 2011 WL 4352741, at *3 (B.P.A.I. Sept. 9, 2011).
116 Ex parte Bamber, No. 2005-2435, 2005 WL 4779414, at *3 (B.P.A.I. Oct. 13, 2005).
117 THE CHICAGO MANUAL OF STYLE ¶ 5.91 (16th ed. 2010) [hereinafter CHICAGO MANUAL].
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elements, because they also require that the prior art literally or inherently disclose
the function.
Examples of compound nouns that contain a functional element in combination
with a structural element are suture wing, 118 projectile entry sheet,119 latch press, 120
liquid impingement orifices,121 leaving group,122 anchor member,123 closing spring, 124
planarization layer,125 primer sequence,126 membrane eraser,127 permanent wall,128
chemical vapor deposition apparatus,129 topical composition,130 attachment device,131
shipping container,132 anti-icing composition,133 and bee smoker.134 In “suture wing,”
the structure is wing and the function that is required of the wing is that it
sutures.135 In “latch press,” the structure is latch and the function is to press. 136 In
“planarization layer” the structure is layer and the function is planarization. 137 In
“primer sequence,” the structure is sequence and where this sequence must possess
the function of being a primer.138 In “bee smoker,” the structure is a smoker where
the functional term (“bee”) requires that the smoker be configured for smoking
bees.139

Ex parte DiMatteo, No. 2009-009433, 2010 WL 4340291, at *1 (B.P.A.I. Nov. 1, 2010).
Ex parte Hunn, No. 2008-4571, 2008 WL 6678024, at *1 (B.P.A.I. Nov. 21, 2008).
120 Ex parte Iy, No. 2009-003280, 2009 WL 2575680, at *1 (B.P.A.I. Aug. 17, 2009).
121 Ex parte Micheli, No. 2008-2641, 2008 WL 4338023, at *4 (B.P.A.I. Sept. 22, 2008). The
Board explained the separate functional component and structural component of the hybrid
functional element, “We conclude that the limitation ‘liquid impingement orifices’ is functional to the
extent that it requires that the orifices be capable of directing liquid so as to impinge on other such
liquid or an obstacle.” Id.
122 Ex parte Kool, No. 2008-2113, 2008 WL 2389796, at *1 (B.P.A.I. June 11, 2008).
123 Ex parte Dingman, No. 2009-013673, 2010 WL 2505308, at *1 (B.P.A.I. June 18, 2010).
124 Ex parte Rodriguez & Smith, No. 2009-012248, 2011 WL 3871985, at *1 (B.P.A.I. Aug. 29,
2011).
125 Ex parte Doan, No. 2008-1034, 2008 WL 1929970, at *1 (B.P.A.I. May 2, 2008).
126 Ex parte Zheng, No. 2009-007969, 2010 WL 674330, at *2 (B.P.A.I. Feb. 23, 2010).
127 Ex parte Tano, No. 2007-002543, 2009 WL 1796028, at *2 (B.P.A.I. June 22, 2009). The
structural word is “eraser.” The required function is, in effect, “configured to erase a membrane.”
Although the structural word was eraser in this opinion, it should be apparent that the word
“eraser” actually defines a function.
128 Ex parte Underwood, No. 2009-006791, 2010 WL 3803671, at *1 (B.P.A.I. Sept. 27, 2010).
129 Ex parte Mardian, No. 2008-2369, 2008 WL 2321841, at *1 (B.P.A.I. June 5, 2008).
130 Ex parte Student, No. 2010-000438, at *2 (B.P.A.I. Aug. 2, 2011).
131 Ex parte Jordan & Persiani, No. 2009-012302, 2011 WL 2579102, at *1 (B.P.A.I. June 27,
2011).
132 Ex parte Lamstein, No. 2010-001964, 2011 WL 3380898, at *1 (B.P.A.I. Aug. 1, 2011).
133 Ice Ban Am., Inc. & Earth Friendly Chems., Inc. v. Patent of Sears Ecological Applications
Co., LLC, No. 2010-009574, 2010 WL 4913983, at *2 (B.P.A.I. Nov. 30, 2010).
134 Ex parte Younger, No. 2009-002969, 2009 WL 5449462, at *1 (B.P.A.I. Dec. 22, 2009).
135 Ex parte DiMatteo, No. 2009-009433, 2010 WL 4340291, at *1 (B.P.A.I. Nov. 1, 2010).
136 Ex parte Iy, No. 2009-003280, 2009 WL 2575680, at *1 (B.P.A.I. Aug. 17, 2009).
137 Ex parte Doan, No. 2008-1034, 2008 WL 1929970, at *1 (B.P.A.I. May 2, 2008).
138 Ex parte Zheng No. 2009-007969, 2010 WL 674330, at *2 (B.P.A.I. Feb. 23, 2010).
139 Younger, 2009 WL 5449462, at *1.
118
119
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A. Bizarre conversion of a structural word to a word referring to function, and
conversion of a functional word to one that denotes structure.
Please note that compound nouns are potentially confusing, because they might
ordinarily be construed as nouns. Please consider the functional element, “bee
smoker.”140 In this example, what is ordinarily considered to be a structure (a bee), is
converted into a function, and what is ordinarily be interpreted as a function
(smoking) becomes the structure. The potential ambiguity of compound nouns has
resulted, in at least one opinion, in the notion that the compound noun should be
considered as a whole to be either a structure or a function. The opinion was Ex
parte Fazekas.141 The functional element was “walking surface.”142 The inventor
argued that the element was not functional.143 But the examiner argued that the
element was functional.144 The Board agreed that the writing was functional, writing
that “the ‘walking surface’ is defined by the action that can take place on it,
walking . . . [t]hus we agree with the Examiner that these limitations are
functional.”145 The Board concluded that the “joist protector” of the cited prior art
was capable of being walked upon, and held that the claim was invalid. 146 The
holding that “walking surface” is a functional element is consistent with all, or nearly
all cases from the Board where the issue was a compound noun.
B. Example of claim construction, where the compound noun is “suture wing.”
Ex parte DiMatteo concerned a claim to a medical device.147 The compound noun
was “suture wing.”148 The cited prior art was Kovacks. The claim in dispute was as
follows.
[Claim] 1. A medical device for percutaneous access to a body comprising: a
housing . . . and a first detachable suture wing selectively coupleable to
the medical device.149
In contemplating the function of “suture,” the Board wrote that:
The Examiner’s argument that Kovacks’ strap portions are capable of
receiving sutures and are therefore suture wings . . . is unpersuasive. The
examiner has not provided any scientific evidence or technical reasoning to
establish that the method[s] [of Kovacks] . . . are, in fact, penetrable by a
surgeon’s suturing instrument. . . . Thus, the examiner has not established
Id.
Ex parte Fazekas, No. 2010-005303, 2012 WL 3766651, at *1 (B.P.A.I. Aug. 24, 2012).
142 Id. at *2.
143 Id.
144 Id.
145 Id.
146 Id.
147 Ex parte DiMatteo, No. 2009-009433, 2010 WL 4340291, at *1 (B.P.A.I. Nov. 1, 2010).
148 Id.
149 Id.
140
141
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that the penetrability . . . is a characteristic that necessarily flows from the
teachings of the applied prior art.150
In a nutshell, the Board held that the functional element “suture wing” was
successful in maintaining claim validity. 151
C. The danger of collapsing both structure and function into one word.
While compound nouns are a shorthand version of a typical functional element,
where the function is distinct from the structural element, even more extreme is the
case where one word serves as both the structural element and the functional
element. Examples include plasticizer, catalyst, anti-oxidant, toaster, stapler, and
filter. The danger of using this type of claim element is that the attorney or agent
might overlook the fact that it can be anticipated (and rendered invalid) by a wide
variety of structures found in the prior art, where anticipation requires only a
matching function, and does not require any matching structure. To repeat, the
danger of using a compound noun, such as “plasticizer,” is that the compound noun
can be anticipated by any chemical in the world that happens to possess the function
of plasticizing.
Ex parte Dillenbeck illustrates this danger, where the disputed claim term was
“plasticizer.”152 The claim was rejected because a prior art compound that was a
“dispersing agent” was alleged to be capable of performing a plasticizing function. 153
In rejecting the claim, the examiner observed that certain compounds known as
“dispersing agent[s]” had properties and functions that overlapped with those of the
plasticizer recited in the claim.154 This author suggests that instead of using the
term “plasticizing agent,” the inventor might have instead used “sulfonic acid-based
plasticizer” or “polyacrylate-based plasticizer.”155 Although these suggested terms
are narrower than the term “plasticizer,” they would be expected to confer a greater
degree of resistance of the claim to invalidation.
Compound nouns that take the form of only one word have been documented by
The Chicago Manual of Style.156 This manual refers to this type of noun as an
“adjective-to-noun” transition, where examples include the transition of “collective
object” to “collectible,” or the transition of “postmortem examination” to
“postmortem.”157

Id. at *2.
Id. at *3.
152 Ex parte Dillenbeck, No. 2009-004202, 2010 WL 1220239, at *1 (B.P.A.I. Mar. 26, 2010).
153 Id. at *7.
154 Examiner’s Answer, U.S. Patent Application No. 11/013,931, at 4 (June 26, 2008).
155 Specification, U.S. Patent Application No. 11/013,931, at 7 (Dec. 16, 2004).
156 CHICAGO MANUAL, supra note 117, ¶ 5.92.
157 Id.
150
151
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D. The danger of combining a functional word with a relatively meaningless word that
refers to a structure.
Another danger of using a compound noun is the temptation to use a bona fide
function in combination with a meaningless word—meaningless in that it requires no
particular structure or no particular range of structures. Ex parte Dingman provides
an example of this danger, where a compound noun (“anchor member”) was used,
where the functional word (“anchor”) referred to a genuine function, but the
associated word that was intended to confer structure (“member”) actually did not
confer any structure at all.158 Other words that are sometimes used as structural
elements, but fail to require any particular structure, are “device,” “element,”
“component,” and “structure.”

158

Ex parte Dingman, No. 2009-013673, 2010 WL 2505308, at *1 (B.P.A.I. June 18, 2010).
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VII. “ACTIVE-TYPE” VS. “CAPABLE-OF-TYPE.”
The difference between an “active-type” functional element and a “capable oftype” functional element is revealed by the following question. Which is better, to
draft a claim reading, e.g., “a device comprising a lever and a gear that sews
buttons,” or “a device comprising a lever and a gear that is capable of sewing
buttons”?
A. Introduction.
The following is an issue that directly confronts every attorney or agent who
takes pen in hand, and begins to draft a claim set. This issue is separately relevant
to the maintenance of claim validity (anticipation or obviousness) and to the claim’s
ability to encompass infringing activities of competitors. This issue is described by
way of a concrete example of a claim to a sewing machine.
The question is, is it better to write the functional element (bold) as:
“A device comprising a lever and a gear that sews buttons,”
or as:
“A device comprising a lever and a gear that is capable of sewing
buttons”?
Functional elements using capable of-type language include recitations of
“wherein the device is capable of,” “wherein the device is configured for,” and
“wherein the device is adapted for.” In contrast, functional elements using activetype language include recitations that the claimed invention “radially compresses,”
“inhibits inflammation,” or “resists oxidation,” to give three examples. The context of
these three examples is disclosed in Table 1.
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Table 1. Claims having active-type functional elements. Functional element
shown in bold.
U.S. Patent

Active-type
functional
element

Context in claim showing position
of active-type functional element

U.S. Pat. No.
8,052,732 issued to
Mitchell et al.159

“[R]adially
compresses”160

“[Claim] 15.
The delivery
system of claim 13 wherein said
primary
sheath
radially
compresses
said
endoprosthesis.”161

U.S. Pat. No.
6.372,456 issued to
Wei et al.162

“[I]nhibits
inflammation”163

“[Claim] 148. An isolated
polynucleotide
comprising
a
nucleic acid sequence selected from
the group consisting of . . . a
nucleic acid sequence encoding a
fragment of SEQ ID NO:2, wherein
said
fragment
inhibits
inflammation.”164

U.S. Pat. No.
5,628,617 issued to
Dalton et al.165

“[R]esists
oxidation”166

“[Claim] 1. In a steam turbine
having a main inlet pipe . . . the
improvement which comprises a
ring carrier replacing the bell seal,
a stack of inner and outer sealing
rings loosely sleeved on the ring
carrier . . . the inner rings being
made from a high strength super
alloy which resists oxidation.”167

U.S. Patent No. 8,052,732, at [10], [75] (filed Nov. 14, 2006).
Id. col.12 l.21.
161 Id. col.12 l.20–21.
162 U.S. Patent No. 6,372,456, at [10], [75] (filed Oct. 23, 1998).
163 Id. col. 60 l.22.
164 Id. col. 60 l.16–22.
165 U.S. Patent No. 5,628,617, at [11], [75] (filed Aug. 12, 1996).
166 Id. col.8 l.29.
167 Id. col.8 l.10–36.
159
160

[13:251 2014] Functional Elements in Patent Claims, as Construed by
the Patent Trial and Appeal Board (PTAB)

279

Other examples are footnoted, that is, where one claim actually requires
reduction of inflammation,168 while another claim only requires the capability of
reducing inflammation.169
When drafting a claim to a device or to a composition of matter, and when faced
with the decision of using active-type language versus capable of-type language,
please note that the claim element that uses capable of-type language does not
impose any requirement that the device or composition actually perform the
function.170 A claim that uses “capable of”-type language covers devices that have the
recited components and which are capable of performing the recited functions.171
The following concerns active-type functional language. Where active-type
functional language is used, it is self-evident that this covers infringing devices that
actively perform what is described by the claim. But also note that case law from the
Board establishes that active-type functional language covers infringing devices that
are not being used by any operator. In other words, case law from the Board
establishes that active-type functional language covers infringing devices that are
merely determined to be capable of performing that function, as established by the
cited cases. In all of the cited cases, the prior art references disclosed devices or
compositions, but failed to have any literal disclosure that the function was
performed. Instead, it was the case that in all of the cited cases, the Board
determined that the function was disclosed by inherency. In these opinions, the
active-type functional element was found to be anticipated by the inherently
disclosed functions.172
B. In methods claims, active-type functional language confers greater resistance to prior
art rejections.
In method claims, differences in validity analysis materialize, when comparing
validity analysis of claims possessing active-type versus claims possessing capable oftype functional elements. The following demonstrates that an active-type functional

168 U.S. Patent No. 7,888,479, at [10], [75], col.148 l.20–21 (filed Nov. 25, 2003). In the patent,
issued to De Fougerolles, claim 43 requires that the claimed composition of matter actually reduces
inflammation: “43. An immunoglobin or antigen-binding fragment of claim 1, which reduces
inflammation in a subject.” Id. col.148 l.20–21.
169 U.S. Patent No. 7,060,286, at [10], [75], col.11 l.7–col.8 l.4 (filed Feb. 13, 2004). In the
patent, issued to Chung, we find a claim that merely requires that the claimed composition of
matter be “capable” of reducing inflammation: “7. An external preparation comprising: oleaginous
substances extracted from . . . spores . . . and a cosmetically acceptable carrier . . . wherein said
topical formulation is capable of reducing inflammation.” Id. col.11 l.7–col.8 l.4.
170 Ex parte Grischenko, No. 2009-001236, 2010 WL 889705, at *3 (B.P.A.I. Mar. 10, 2010).
171 Ex parte Aflekt, No. 2007-2815, 2007 WL 2823738, at *2 (B.P.A.I. Sept. 27, 2007).
172 Ex parte Aufderheide & Frank, No. 2007-3175, 2008 WL 752643, at *5 (B.P.A.I. Mar. 20,
2008); Ex parte Baker, No. 2006-2892, 2007 WL 630236, at *3 (B.P.A.I. Feb. 26, 2007); Ex parte
Hougham, No. 2008-2787, 2009 WL 211774, at *6 (B.P.A.I. Jan. 27, 2009); Ex parte Kimijima, No.
2009-1994, 2009 WL 1288569, at *5 (B.P.A.I. May 8, 2009); Ex parte Kamimura, No. 2009-007132,
2010 WL 4018662, at *2–3 (B.P.A.I. Oct. 12, 2010); Ex parte Newman, No. 2008-5922, 2009 WL
803079, at *4–5 (B.P.A.I. Mar. 25, 2009); Ex parte Schembri, No. 2008-2978, 2009 WL 492114, at *6
(B.P.A.I. Feb. 25, 2009); Ex parte Waldmann, No. 2011-003005, 2011 WL 2661226, at *3 (B.P.A.I.
July 6, 2011).
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element confers greater resistance to the claim against prior art rejections, than with
a capable of-type functional element. This benefit is possible only in method claims,
and not claims to devices.
Ex parte Newton addresses the issue of whether a functional element should be
expressed in terms of what the device is capable of, or in terms of what the device
actually does.173 Ex parte Newton concerned two claims, Claim 1 and Claim 15, as
shown below.174 The cited prior art was Sprigg.175
Claim 1 is a claim to a device, where the claim requires that the device is merely
capable of doing something.176 The capable of-type language is bolded.
1. A device comprising . . . a storage management unit for allocating a
portion of the local storage arrangement . . . and referencing the
portion with identification information respecting respective access
rights.177
In contrast, Claim 15 is a claim to a method, where the claim requires actually
doing the same thing.178 The active-type language is bolded.
15. A method for managing a local storage arrangement in a device
comprising:
allocating a portion of the local storage
arrangement . . . and, including in the portion identification information
respecting the access rights.179
The Board performed separate validity analyses for claim 1 and claim 15,
regarding the use of the Sprigg reference to invalidate these claims. 180 The Board
observed that “Sprigg’s storage management unit references identifying
information . . . [and that] Sprigg’s identifying information is capable of granting
access rights.”181 In view of this observation, the Board held that claim 1 was
invalid.182 But regarding claim 15, the Board held that “Sprigg does not actually
grant access rights to the software application,” and in view of this, refrained from
holding that claim 15 is invalid.183
The take-home lesson is that active-type functional language can be more
resistant to prior art rejections than capable of-type functional language, but only for
methods claims.184
Ex parte Newton, No. 2009-010083, 2011 WL 1536023, at *5 (B.P.A.I. Apr. 21, 2011).
Newton, 2011 WL 1536023, at *1.
175 Id.
176 Id.
177 Id.
178 Claims, U.S. Patent Application No. 10/575,412, at 1 (Apr. 10, 2006).
179 Id. at 2.
180 Newton, 2011 WL 1536023, at *2–4.
181 Id. at *3.
182 Id. at *4.
183 Id. at *5.
184 Ex parte Laing, No. 2009-005770, 2010 WL 1170483, at *4 (B.P.A.I. Mar. 25, 2010); Ex parte
Harris, No. 2007-2377, 2007 WL 5108546, at *4–5 (B.P.A.I. Sept. 19, 2007); Ex parte Barnhill, Jr.,
No. 2007-3077, 2007 WL 5151254, at *10 (B.P.A.I. Sept. 26, 2007); Ex parte Hill & Casper, No. 2009012902, 2010 WL 3728725, at *6 (B.P.A.I. Sept. 22, 2010); Ex parte Tarenskeen, Jr., No. 2008173
174
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Where active-type functional language is used, this may result in the risk of an
indefiniteness rejection, involving allegations that the claim is a mixture of a device
claim and method claim. This author recommends using only capable of-type
language, in view of the fact that it unambiguously requires that the associated
structure be capable of performing the indicated function, and because it
unambiguously avoids suggesting that the structure actually perform that function.
Also, this author recommends avoiding using “capable of” language for some
claims, and “active type” language for other claims, because of established case law
that holds that when different terms are used in separate claims, they are presumed
to have different meanings.185 This author recommends against drafting a variety of
different terms that mean “capable of,” and instead make uniform use of “capable of.”
C. The “impossible standard” for being “capable of” is a strict set-point.
In determining if a prior art reference is capable of performing any given
function, it is not particularly relevant if the prior art can perform the function, but
only with great difficulty or inconvenience. The only thing relevant is whether it is
absolutely impossible that the prior art be capable of performing the function. If it is
absolutely impossible, then the prior art cannot be invalidating against the claim.
Ex parte Justis concerned the following claim.186 The functional element is in
bold. The invention was a spinal rod for fusing vertebra in the spine. 187
[Claim] 1. A connector . . . comprising . . . a fastener configured to mate
with the receiver to maintain the longitudinal member in the channel, a
force applied by the fastener to maintain the longitudinal rod
within the channel.188
The claim was rejected for anticipation in view of the Shluzas prior art. 189 The
inventor attempted to rebut the rejection, arguing that using the Shluzas device to
perform the inventor’s process would be difficult and inconvenient. 190
The
inconvenience was that to use the Shluzas disclosure for practicing the claim “would
require a patient to be strapped down to an operating table, inverted, and for the
connector to be inserted into the patient while the patient is in this orientation.” 191
005079, 2010 WL 581985, at *4 (B.P.A.I. Feb. 17, 2010). In Ex parte Britt, the opinion stated that
“[t]he examiner responds that the billing function recited in the claim is not positively claimed but
only requires that the element be able to perform the function.” Ex parte Britt, No. 2009-006557,
2010 WL 2070567, at *7 (B.P.A.I. May 21, 2010). Here, the Board clearly distinguishes between the
efficacy of “active-type” functional language versus “capable of”-type functional language to resist
prior art rejections.
185 Comark Commc’ns, Inc. v. Harris Corp., 156 F.3d 1182, 1187 (Fed. Cir. 1998); Aspex
Eyewear, Inc. v. Marchon Eyewear, Inc., 672 F.3d 1335, 1349 (Fed. Cir. 2012).
186 Ex parte Justis & Molz IV, No. 2010-001025, 2011 WL 3791632, at *1 (B.P.A.I. Aug. 22,
2011).
187 Id.
188 Id.
189 Id. at *2.
190 Id.
191 Appeal Brief, U.S. Patent Application No. 11/341,239, at 7 (May 11, 2009).
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The Board affirmed the rejection, writing that “inconvenience alone does not preclude
the possibility that the procedure could be performed while the patient is
inverted.”192
A similar fact pattern is found in Ex parte Putre, which involved the following
claim:
[Claim] 1. A work stand comprising . . . a collar slidable on said support
member . . . and links between said collar and said legs for displacing
said legs between expanded and retracted positions.”193
The cited prior art was Dalton, which disclosed a knob, leg assembly, and
tripod.194 The inventor attempted to persuade the Board that Dalton was incapable
of performing the function.195 However, the Board held that Dalton was merely
awkward in performing the function, writing, “[f]urther, while it might be awkward
for a user to grasp the knob 22 when the leg assemblies are folded due to space
constraints, it does not appear to be impossible.”196 Thus, Ex parte Putre provides the
“impossible standard” for assessing whether or not the cited prior art is capable of
performing the function set forth in the functional element.
The “impossible standard” was also vividly set forth by Ex parte Cho, which
concerned the functional element “pre-shrunk.”197 The Board held that any prior art
that discloses a structure that is “pre-shrunk” is invalidating prior art, even if the
amount of pre-shrunkedness is minimal.198 In the Board’s words:
[T]he claim encompasses a fabric having properties resulting from any
amount of pre-shrinking however minuscule that amount may be. It is
reasonable to conclude that the pre-shrunk structure resulting would be
the same or substantially the same as the structure of the prior art fabric
containing PMP hollow membrane fibers whether shrinking has occurred
or not.199
The take-home lesson is that inventors should not expect arguments relating to
difficulty, inconvenience, or awkwardness to be successful in rebutting an inherencybased rejection that is directed against a functional element.
VIII. TECHNIQUES FOR REBUTTING REJECTIONS AGAINST A CLAIM.
The following is a practical guide on rebutting rejections against a claim that
has a functional element.
Justis, 2011 WL 3791632, at *2.
Ex parte Putre, No. 2008-1701, 2008 WL 3874449, at *1 (B.P.A.I. Aug. 19, 2008).
194 Id. at *2.
195 Id. at *4.
196 Id. at *3.
197 Ex parte Cho, No. 2005-1608, 2005 WL 4773370, at *1 (B.P.A.I. Sept. 22, 2005).
198 Id. at *4.
199 Id. at *3. For a similar fact pattern, see Ex parte Ericson, No. 2010-010875, 2012 WL
5982978, at *3 (B.P.A.I. Nov. 26, 2012).
192
193
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A. Opposite function.
The most dramatic technique for rebutting an allegation that the prior art
discloses the same function as that of the claim’s functional element is to argue that
the prior art discloses the opposite function.
Ex parte Schneider concerned the following.200 The prior art was the Naor
patent.201 In the claim, the functional element is associated with a structure, where
this structure is a “controller.”202
[Claim] 1. A welding-type system comprising: a plasma torch controlled by
a trigger and constructed to generate an arc . . . and a controller
configured to control the air supply . . . and if arc outage is
detected . . . cause (1) continued air flow through the plasma torch
for a predetermined period and (2) then regenerate a pilot arc in
the plasma torch.203
According to the opinion, “[t]he examiner took the position that the functional
limitations of the controller . . . are inherent characteristics of the prior art.”204
The inventor pointed out that the Naor prior art disclosure taught the opposite
of what was required by the functional element. 205 Where an arc outage occurs, the
claims require that air continue to flow for a predetermined period, and that after
this period the arc be regenerated.206 But in contrast, Naor requires that:
[w]hen an arc outage is sensed . . . controller 109 causes air solenoid 307 to
interrupt the air supply and vent the torch . . . and a pilot arc is
reinitiated.207
In the inventor’s argument, the inventor identified this part of the Naor patent.
The inventor stated that, “[i]t is clear from even a cursory review of Naor . . . that
what is called for in claim 1, specifically the continued air flow through the torch, is
not anticipated by that which is disclosed in Naor.”208 The Board agreed with the
inventor, reversed the rejection, and held that the claim was allowable over the prior
art.209

Ex parte Schneider, No. 2008-4677, 2009 WL 191989, at *1 (B.P.A.I. Jan. 26, 2009).
Id.
202 Id.
203 Id.
204 Id. at *5.
205 Id.
206 Id.
207 U.S. Patent No. 5,828,030, at [11], [75], col.7, l.11–27.
208 Appeal Brief, U.S. Patent Application No. 10/905,420, at 7 (June 29, 2007).
209 Schneider, 2009 WL 191989, at *6.
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B. Declaration from an expert.
1. Example of Ex parte Sanocki.
Ex parte Sanocki concerned a catalytic converter.210 The cited prior art was
Stroom.211 The disputed claim was as follows. The associated structural element is
“insert.”212
[Claim] 1. A pollution control device comprising . . . at least one resilient,
flexible, fibrous non-intumescent insert.213
The inventor’s goal was to convince the court that Stroom did not disclose a
composition that functioned as resilient and flexible. 214 The inventors submitted a
declaration from an expert in ceramic engineering.215 The declaration revealed an
experiment providing side-by-side laboratory data that compared resiliency of an
example (“example 38”) from Stroom with an example of the inventor. 216 The data in
the expert’s declaration distinguished the Stroom reference from Claim 1. 217 This
declaration is an excellent model for attorneys and agents to follow for use in
prosecuting patent applications in any technology.
Regarding expert declarations, Ex parte Lamstein expressly suggested that
inventors submit declarations, where the goal is to persuade the court that a cited
prior art reference is not capable of performing the function in question. 218
2. Example of Ex parte Santos.
Ex parte Santos concerned a pharmaceutical composition that masks a badtasting drug that is part of the composition. 219 The cited prior art was White. 220 The
claim was as follows, where the two functional elements are highlighted in bold.
[Claim]
1.
A
taste-masked
liquid
pharmaceutical
composition . . . comprising: at least one unpleasant tasting drug;

Ex parte Sanocki, No. 2008-2497, 2008 WL 2553081, at *1 (B.P.A.I. June 25, 2008).
Id. at *2.
212 Id. at *1.
213 Id.
214 Id. at *4.
215 Id. at *4. Declaration of Gary G. Howorth, U.S. Patent Application No. 10/652,838, at 3–5
(June 21, 2007).
216 Id. at 3.
217 Id. at 4–5.
218 Ex parte Lamstein, No. 2010-001964, 2011 WL 3380898, at *3 (B.P.A.I. Aug. 1, 2011).
219 Ex parte Santos, No. 2006-0251, 2006 WL 1665493, at *1 (B.P.A.I. Apr. 28, 2006).
220 Id.
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polyethylene glycol . . . and polyvinyl pyrrolidone . . . wherein a final form of
said taste-masked pharmaceutical composition . . . is a liquid.”221
The inventor submitted a declaration from an expert that demonstrated that the
cited prior art (White) was not capable of performing the function. 222
The
declaration, which was written by a researcher with a Ph.D. in chemical engineering,
disclosed the following taste test.223 The experiment involved human subjects, where
the subjects were asked to drink water and take unsalted crackers between samples
to remove traces of the first sample tested. 224 The experiment involved tasting only
samples prepared according to the White reference. The result of the tasting test
was that a composition made according to White’s example VIII was “unacceptably
bitter.”225 The Board was persuaded by the inventor’s rebuttal, and the Board held
that the claims were valid.226
C. Include a bank of claim limitations in the specification.
Another technique for rebutting rejections against functional elements is to draft
a bank of potential claim limitations into the specification. This bank consists of a
list of progressively narrowing aspects of the same function.
Where a functional element includes a term, such as “inhibits,” “resists,”
“prevents,” “lowers,” “compresses,” “dampens,” “enhances,” or “increases,” or any
term that can be characterized by a scientific unit (speed, velocity, density, hardness,
etc.), the patent attorney or agent should include a bank of claim limitations in the
specification for future use. This bank should take the following form, as shown by
way of example: “in alternative embodiments, the present device inhibits oxidation,
where inhibition is at least 5%, at least 10%, at least 15%, at least 20%, at least 30%,
at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%,” and
the like. During prosecution, the attorney might find a need to input the limitation
“inhibition of at least 60%” into the claim. The existence of this bank enables the
attorney to import this limitation to the claims.
Ex parte Bradley provides guidance for enhancing the ability of a functional
element to confer resistance of the claim, when faced with a prior art rejection. 227 In
Ex parte Bradley, the functional element was “sufficient to inhibit oxidation of the
fluorescent label.”228 The examiner rejected the claim, alleging that the chemical
reagents and conditions described in the prior art (Rothberg) were sufficient to
inhibit this type of oxidation.229 Please note that “inhibition” is a concept that can be
expressed in terms of a unit, where the unit is “percent.”

Id.
Declaration of Kennie U. Dee, U.S. Patent Application No. 10/017,697, at 3 (Apr. 30, 2004).
223 Id. at 1, 8.
224 Id. at 8.
225 Id. at 6.
226 Santos, 2006 WL 1665493, at *3–4.
227 Ex parte Bradley & Cai, No. 2008-1184, 2008 WL 2125177, at *7–8 (B.P.A.I. May 19, 2008).
228 Id. at *1.
229 Id. at *2.
221
222

[13:251 2014] The John Marshall Review of Intellectual Property Law

286

The Board affirmed the rejection, writing: “because claim 28 does not recite any
particular level of oxidation inhibition, claim 28 encompasses even miniscule levels of
inhibition.”230
But from this opinion, the take-home lesson is that the specification should have
included a bank of claim limitations suitable for inputting into the claim element,
that is, by way of an amendment following the rejection. This bank could have taken
the form of “sufficient to inhibit oxidation by at least 80%,” “sufficient to inhibit
oxidation by least 90%,” “sufficient to inhibit oxidation by at least 95%,” and
“sufficient to inhibit oxidation by at least 99%.”
This type of bank of limitations is conventional in the patent drafting art. The
patent application in Ex parte Bradley231 did contain banks of progressively
narrowing limitations, where these banks concern parameters such as temperature,
concentration of reagents, molecular weight, ranges of viscosity, ability to inhibit
oxidation, and so on. But there was no bank of limitations relating to percent
inhibition. The take-home lesson is that every functional element drafted into the
claim set should have a corresponding bank of progressively narrowing limitations,
drafted into the specification before submitting the patent application to the Patent
Office.
D. Arguments that a functional element is really a structural element, or that a
structural element is really a functional element.
Where it is alleged that a particular claim element is functional, and if it is to
the inventor’s advantage to argue that the element is really structural, the inventor
should explore avenues for drafting and submitting this type of argument. The cited
cases list most if not all of the cases where the Board’s opinion contained inventor’s
arguments that an element that was allegedly a functional element was really a
structural element.232
Ex parte Krause concerned a claim to an apparatus for use with a mixing bag,
where the apparatus included the mixing bag.233 The functional element related to
the direction of impeller that moved around in the bag.234 The claim in question was
as follows:

Id. at *7.
Id.; Specification, U.S. Patent Application No. 10/207,440, at 6 (July 26, 2002).
232 Ex parte Perez-Cruet, No. 2010-007447, 2012 WL 32279, at *5 (B.P.A.I. Jan. 3, 2012); Ex
parte Sauer, No. 2011-010199, 2012 WL 4042827, at *3 (B.P.A.I. Sept. 7, 2012); Tempo Lighting v.
Patent of Tivoli LLC, No. 2011-012102, 2012 WL 627809, at *9 (B.P.A.I. Feb. 24, 2012); Ex parte
Bemis, No. 2006-2036, 2006 WL 2786857, at *2 (B.P.A.I. Sept. 25, 2006); Ex parte Fazekas, No.
2010-005303, 2012 WL 3766651, at *2–3 (B.P.A.I. Aug. 24, 2012); Ex parte Johnson, No. 2010005357, 2011 WL 5013824, at *2 (B.P.A.I. Oct. 17, 2017); Ex parte Lipscomb, No. 2009-004292, 2009
WL 3165389, *4–5 (Oct. 2, 2009); Ex parte Ota, No. 2009-005055, 2010 WL 676165, at *2 (B.P.A.I.
Feb. 24, 2010); Ex parte Piepgras, No. 2009-010531, 2011 WL 1576586, at *4 (Apr. 25, 2011); Ex
parte Shaw, No. 2010-003526, 2011 WL 4009524, at *3 (B.P.A.I. Aug. 31, 2011); Ex parte
Stadelhofer, No. 2009-008536, 2010 WL 4018666, at *2 (B.P.A.I. Oct. 12, 2010); Ex parte
Underwood, No. 2009-006791, 2010 WL 3803671, at *3 (B.P.A.I. Sept. 28, 2010).
233 Ex parte Krause, No. 2009-0371, 2009 WL 537183, at *1 (B.P.A.I. Mar. 3, 2009).
234 Id.
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[Claim] 4. An apparatus for mixing fluid, comprising: a mixing bag formed
of a flexible material, an impeller connected to a shaft within the mixing
bag, wherein a portion of the shaft traverses the mixing
bag . . . opposite a . . . base portion of the mixing bag.235
In an attempt at arguing that the prior art (Bibbo) was distinguished from the
claims, the inventor provided a drawing of the claimed device, showing a long mixing
shaft reaching from the top all the way down to the bottom of the bag (for mixing the
base portion), and a drawing of the Bibbo device, showing a short shaft coming out
from the bottom of the bag (for mixing the base portion). 236 In viewing the dictionary
definition of the word, “traverses” (the functional element in the claim contains this
word), it is apparent that “traverses” compels a particular structure. 237 The
dictionary definition of “traverses” means moving all the way across.238 To repeat,
the word “traverses” mandates a particular dimension to the shaft, with respect to
the mixing bag.
The inventor argued that “[t]his claim limitation is devoid of intended-use or
method-of-use language, and only defines a location of a physical structure.
Therefore, the limitation should be afforded patentable weight for differentiating [the
inventor’s] Claims from the prior art.”239
Although the inventor’s argument in Ex parte Krause did not succeed,240 this
case is an excellent teaching example of how to argue that an alleged functional
element is really structural.
Similarly, Ex parte Cho discloses the fact-pattern where the inventor argued
that one particular claim element was structural, but where the Board held that the
element was a functional element.241 The claim contained the phrase, “pre-shrunk
microporous membrane fabric.”242 The disputed claim element was “pre-shrunk.”243
This element, which the examiner argued was functional, was associated with the
structure, “microporous membrane fabric.”244
This author points out that “preshrunk” can be characterized as functional, because it refers the function of the fabric
as being resistant to further shrinking. On the other hand, this author also points
out that “pre-shrunk” is structural, because the term refers to a dimension, that is, a
size dimension, and because any “pre-shrunk” fabric is likely to have a unique
footprint when viewed by electron microscopy.
The inventor argued that “pre-shrunk” was a structural element, because the
prior art documents that were cited in the rejection failed to disclose the term “preshrunk.”245 Unfortunately, the inventor’s arguments were totally conclusory. The
Id.
Id.; Appellant’s Reply Brief, U.S. Patent Application No. 10/838,576, at 5 (Feb. 25, 2008)
[hereinafter 10/838,576 Reply Brief].
237 MERRIAM-WEBSTER’S COLLEGIATE DICTIONARY 1332 (11th ed.).
238 Id.
239 10/838,576 Reply Brief, supra note 236, at 7.
240 Krause, 2009 WL 537183, at *4.
241 Ex parte Cho, No. 2005-1608, 2005 WL 4773370, at *2 (B.P.A.I. Sept. 22, 2005).
242 Id. at *1.
243 Id.
244 Id.
245 Id. at *2, *4.
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inventor failed to argue that “pre-shrunk” mandated a particular dimension. The
conclusory argument was “pre-shrunk is a structural limitation describing the
microporous membrane fabric of the instant invention.”246
The Board took the following approach for determining if “pre-shrunk” is
functional or structural. Established case law holds that the court must explore the
specification of the patent for guidance on the meaning of claim terms. 247 The Board
explored the specification for guidance on the meaning of “pre-shrunk,” and found the
following writing: “a preferred method of preshrinking and stabilizing the fabric is to
heat the fabric to about 15ºC above the expected operating temperature for
approximately 2 to 8 hours.”248 In view of this functional characterization, the Board
found that it related to the function of heating a fabric, and reasonably concluded
that “pre-shrunk” is a functional element. 249 In holding that the term “pre-shrunk”
was functional, the Board observed that the cited prior art disclosed a structure that
corresponded to the claim, and affirmed the rejection of the claim. 250
Ex parte Hall is another case where the examiner argued that a word (“lid”) was
functional, while the inventor argued that the same word (“lid”) was structural.251 In
this case, the Board dispensed with the conventional structural definition of the word
“lid” and, in assessing the anticipation by the prior art, only took into account the
functional aspects of this word.252 The prior art was U.S. Pat. No. 571,349 issued to
Farquhar, “Combined Dough-Board and Bread-Cutting Tray,” dating from 1896.253
The inventor fruitlessly argued that the prior art device is not a lid, and pointed out
that dictionaries define a “lid” as a moveable cover for opening a hollow container,
and that the Farquhar patent does not disclose any container. 254 Nevertheless, the
Board held that the Farquhar device was capable of functioning as a lid. 255 The
result is that the claim was rendered invalid. 256 This holding of invalidity stemmed
from the Board’s refusal to accept the conventional use of the word “lid” as referring
to a structure.257 This case illustrates the danger of allowing an adverse party to
argue that a particular element is functional.
Ex parte Johnson is similar to Ex parte Hall in that it provides the fact pattern
where the examiner argued that the structural features of a word (“pore”) did not
exist, and that the meaning of the word “pore” was only the function of a pore. 258
However, the Board restored the structural meaning of the word “pore,” where this

Appeal Brief, U.S. Patent Application No. 10/424,327, at 11 (Dec. 9, 2004).
Brody, Contexts of Implication, supra note 9, at *3; Hockerson-Halberstadt, Inc. v. Avia
Group Int’l, Ltd., 222 F.3d 951, 955 (Fed. Cir. 2000).
248 Cho, 2005 WL 4773370, at *2.
249 Id.
250 Id. at *4.
251 Ex parte Hall, No. 2011-012859, 2011 WL 5080234, at *5 (B.P.A.I. Oct. 22, 2011).
252 Id. at *4.
253 Id. at *2; U.S. Patent No. 571,349.
254 Hall, 2011 WL 5080234, at *2–3.
255 Id. at *4.
256 Id. at *5.
257 Id. In this author’s opinion, the inventor should have submitted a Declaration under 37
CFR § 1.132 regarding the definition of “lid” according to one skilled in the art.
258 Ex parte Johnson, No. 2009-004294, 2009 WL 3044472, at *4 (B.P.A.I. Sept. 22, 2009).
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restoration was based on the Board’s reference to the meaning that was understood
by the skilled artisan.259
The Federal Circuit in Acco Brands, Inc. v. Micro Security Devices, Inc. also
addressed the issue of whether a particular element was structural or functional.260
In this opinion, if the element was structural, the claim would be broader in scope,
but if functional, the claim would have narrower scope.261 This case is on point to a
recurring problem in patent prosecution, namely the meaning of the word “when.”
Acco Brands provides the warning that where “when” refers to a specific moment in
time, the element is functional, but where “when” refers to the ongoing status of a
device, the element is structural. 262 The court followed the conventional hierarchy of
claim construction, reviewed the specification for guidance, and held that “when”
referred to a specific moment in time, and that the element was functional.263
To conclude, an attorney or agent might consider scrutinizing the draft claims,
and replacing words that could be construed as either structural or functional (e.g.
“traverses” or “pre-shrunk”) with words that can only be interpreted as structural.
In general, functional elements place a claim at greater risk to invalidation from
prior art references in technologies that are remote from that of the claim, and also
place a claim at greater risk for inherency-based rejections under In re Schreiber.264
Functional elements may be more susceptible to rejections, in view of In re
Schreiber,265 which can shift the burden to the inventor to prove the cited prior art is
incapable of performing the function.

E. Impermissible hindsight.
Impermissible hindsight, also known as “hindsight reconstruction,” has a basis
in, for example, Graham v. John Deere Co.,266 W.L. Gore and Associates, Inc. v.
Garlock, Inc.,267 In re Fritch,268 and In re Wesslau.269 The term “hindsight” means
that, in imposing an obviousness rejection, the examiner had made excessive use of
the inventor’s patent application as instruction manual or template for seeking out
the prior art, or for picking and choosing elements from within one particular prior

Id.
Acco Brands, Inc. v. Micro Sec. Devices, Inc., 346 F.3d 1075, 1077 (Fed. Cir. 2003).
261 Id. at 1080.
262 Id. at 1078.
263 Id. at 1079; Brody, Contexts of Implication, supra note 9, Table 1.
264 In re Schreiber, 128 F.3d 1473, 1479 (Fed. Cir. 1997).
265 Id. at 1478. In re Schreiber concerns validity analysis—that is, anticipation analysis and
obviousness analysis. More specifically, this case sets forth a rule for burden shifting during
inherency analysis. The burden is as follows: where an adverse party alleges that the cited prior
art inherency discloses a function, that is, a function that is the same as that recited in the claim’s
functional element, the burden shifts to the inventor. Id. When this happens, the inventor’s burden
is to demonstrate that the prior art cannot perform that function. Id.
266 Graham v. John Deere Co., 383 U.S. 1, 36 (1966).
267 W.L. Gore & Assocs., Inc. v. Garlock, Inc., 721 F.2d 1540, 1553 (Fed. Cir. 1983).
268 In re Fritch, 972 F.2d 1260, 1266 (Fed. Cir. 1992).
269 Application of Wesslau, 353 F.2d 238, 241 (C.C.P.A. 1965).
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260

[13:251 2014] The John Marshall Review of Intellectual Property Law

290

art reference.270 In other words, the Patent Office Boards (the P.T.A.B. and the
B.P.A.I.) have complained that an examiner’s rejections made use of impermissible
hindsight in selecting the prior art references from the prior art, and have also
complained that the examiner had used impermissible hindsight to select structures
from different examples that are all disclosed in one particular prior art reference.271
“Impermissible hindsight” is frequently used by the Patent Office and the
Federal Circuit as a basis for reversing obviousness rejections. The Board has
observed that a bright-line rule for impermissible hindsight has not been provided by
the Federal Circuit, writing that, “[w]e are cognizant that our reviewing courts have
not established a bright-line test for hindsight.”272 Inspired by this failure, the
author reviewed about 500 cases from the Board, and detected the following
categories of impermissible hindsight. The author selected these 500 cases because
the Board had invoked “impermissible hindsight” and that, as a consequence,
reversed the examiner’s obviousness rejection. The categories include the following:
(1) Unneeded advantage. Where the secondary reference disclosed an
advantage, but where none of the cited prior art references suggested that the
primary reference could benefit from that advantage or was in need of that
advantage.273
(2) Redundant advantage. Where the secondary reference disclosed an
advantage, and where the primary reference already possessed that advantage. 274
(3) Disparity. Where the primary reference and secondary reference were
disparate from each other; for example, where the primary reference was a golf club
and the secondary reference was an underwater observatory, 275 or where the primary
reference was a baby bottle and the secondary reference was an industrial gas
tank.276
(4) Context. Where a structure that was provided by the device of the
secondary reference resided in a context that was dramatically different from the
context of the device of the primary reference.277

W.L. Gore, 721 F.2d at 1553.
Id.
272 Ex parte Kastelewicz & Kim, No. 2008-004808, 2009 WL 1719394, at *6 (B.P.A.I. June 9,
2009).
273 See, e.g., Ex parte Saiki, No. 2000-0373, 2002 WL 32102452, at *3 (B.P.A.I. Jan. 17, 2002);
Ex parte Burak, No. 2004-0823, 2004 WL 4981768, at *4 (Dec. 8, 2004).
274 See, e.g., Ex parte Anttila & Jung, No. 2010-006328, 2012 WL 4718520, at *3 (B.P.A.I. Sept.
27, 2012); Kastelewicz, 2009 WL 1719394, at *5–7; Ex parte Levine, No. 2010-001240, 2012 WL
4483329, at *3 (B.P.A.I. Sept. 25, 2012).
275 Ex parte Miura, No.2002-1488, 2004 WL 4978591, at *1, *2 (B.P.A.I. Mar. 25, 2004).
276 Ex parte Michaels, No. 2006-3175, 2006 WL 4005482, at *1, *2 (B.P.A.I. Dec. 12, 2006).
277 See, e.g., Ex parte Bian, No. 2008-3625, 2008 WL 4418282, *4–5 (B.P.A.I. Sept. 29, 2008); Ex
parte Park, No. 2010-001574, 2012 WL 683692, at *2 (Feb. 28, 2012); Ex parte Oda & Suzuki, No.
2011-001399, 2012 WL 889732, at *2 (B.P.A.I. Mar. 5, 2012); Ex parte Schroeder, No. 2002-1408,
2002 WL 33948433, at *3 (B.P.A.I. Nov. 26, 2002).
270
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(5) Selecting. Where the examiner had used “selection” in picking and choosing
elements from the cited prior art references, for example, by selecting from a long list
of chemicals.278
(6) Optimizing. Where the examiner had invoked routine optimization in
arriving at the obviousness rejection.279
(7) Missing element. Where not all of the elements required by the claim were
disclosed by the combination of the cited references. Most of these opinions
concerned missing structural elements, but some concerned a missing functional
element. The following table lists nearly all of the opinions where the missing
element was a functional element.
(8) Secondary reference provides a disadvantage to primary reference.
The following establishes the category of impermissible hindsight, where the
secondary reference provides a disadvantage to the primary reference. In these
obviousness rejections, the primary reference provided all but one of the elements of
the claim, and the secondary reference provided the missing element. However,
importing the missing element from the device of the secondary reference into the
device of the primary reference resulted in a disadvantage to the device of the
primary reference. In all of the opinions, the Board compared the references with
each other.280
(9) Non-analogous art. Rebuttals that argue for non-obviousness because of
non-analogous art compare a prior art reference with the claim. In all of the cited
cases, the Board characterized the obviousness rejection as based on impermissible
hindsight.281
278 See, e.g., Ex parte Fokken & Reith, No. 2007-1565, 2007 WL 1540195, at *4 (B.P.A.I. May
16, 2007); Ex parte Wofford & James, No. 95-4450, 1995 WL 1696890, at *3–4 (B.P.A.I. May 5,
1999); Ex parte Miller, No. 2001-0120, 2003 WL 23013167, at *2 (B.P.A.I. Dec. 18, 2002).
279 See, e.g., Ex parte Domen & Hara, No. 2010-008469, 2012 WL 3133037, at *2 (B.P.A.I. July
26, 2012); Ex parte Botros, No. 2011-012279, 2012 WL 6824032, at *2 (P.T.A.B. Dec. 17, 2012); Ex
parte Musgrave, No. 2011-009559, 2013 WL 819564, at *8 (P.T.A.B. Feb. 25, 2013); Ex parte Ho, No.
1998-1069, 2002 WL 31234516, at *3, *5 (B.P.A.I. Nov. 26, 2001).
280 Ex parte Adams, No. 2002-1407 (B.P.A.I. Mar. 9, 2003); Ex parte Baiges, No. 2005-1273
(B.P.A.I. July 17, 2005); Ex parte Beggs, No. 1996-2341 (B.P.A.I. Aug. 30, 1999); Ex parte Bemis, No.
2006-2036 (B.P.A.I. Sept. 24, 2006); Ex parte Breiner, No. 2010-011623 (B.P.A.I. Dec. 17, 2012); Ex
parte Coulton No, 2004-1298 (B.P.A.I. June 8, 2004); Ex parte Gilbert, No. 2002-0352 (March 21,
2002); Ex parte Grenier, No. 2011-007921 (B.P.A.I. Dec. 14, 2011); Ex parte Guzzardo, No. 2004-1600
(B.P.A.I. Aug. 11, 2004); Ex parte Hale No. 96-2391 (B.P.A.I. Aug. 10, 1997); Ex parte Ito, No. 2010003391 (B.P.A.I. July 24, 2012); Ex parte Howard, No. 2009-005947 (B.P.A.I. May 25, 2010); Ex
parte Korb, No. 2008-006186 (B.P.A.I. June 30, 2009); Lacks Indus., Inc. v. Hayes Lemmerz Int’l,
Inc., No. 2010-005186 (B.P.A.I. July 9, 2010); Ex parte Lang, No. 2010-000573 (B.P.A.I. Feb. 28,
2012); Ex parte Nakamura, No. 2005-1458 (B.P.A.I. Sept. 28, 2005); Ex parte Perez, No. 2009-015402
(B.P.A.I. Jan. 20, 2011); Ex parte Piorkowski , No. 2010-000592 (B.P.A.I. Sept. 26, 2012); Ex parte
Shane, No. 2005-1115 (B.P.A.I. July 27, 2005); Ex parte Steele, No. 95-0942 (B.P.A.I. July 14, 1997);
Ex parte Umeda, No. 2005-2408 (B.P.A.I. Nov. 17, 2005); Ex parte Zatkulak, No. 2010-007573
(B.P.A.I. June 21, 2012).
281 Ex parte Ziarno, No. 1997-3968 (B.P.A.I. July 1, 2000) (This case is exemplary, because
separately comparing the primary reference with the claim, and also comparing the secondary
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Table 2 discloses nearly all of the opinions from the Patent Office relating to
missing functional elements, where the Board characterized the rejection as
involving impermissible hindsight. To conclude, the Patent Office frequently cites
precedential case law regarding impermissible hindsight in the situation where not
all of the claim elements are disclosed by the cited prior art. This provides an
additional avenue for rebutting obviousness rejections, where the issue was an
allegation that the cited prior art disclosed a functional element. The Federal Circuit
and its predecessor court have also established that obviousness rejections can be
characterized as involving “impermissible hindsight,” in the situation where the cited
references fail to disclose one or more of the elements in the claim. 282

Table 2. Functional element of the claim, where the recited function
was not disclosed in the cited prior art references, in opinions where the
Board held that the rejection was based on impermissible hindsight.
Opinion

Functional element

Ex parte Schweikhardt

“wicking element”283

Ex parte Field

“a squeegee . . . configured
to engage the surface.”284

Ex parte Thomas

“under conditions to
promote nitroreductase
activity.”285

Ex parte Gottis

“wherein the coating
composition flows and cures at
temperatures in the range of

reference with the claim, where each comparison supported the conclusion that non-analogous art
had been cited.); Ex parte Reddy, No. 2002-2318 (B.P.A.I. Apr. 18, 2004); Ex parte Feld, No. 19992783 (B.P.A.I. Jan. 24, 2001). This opinion provides a rebuttal that the claim and a reference are
from non-analogous art, and a separate rebuttal that the cited references are “disparate” from each
other. Id. Thus, this opinion is exemplary in that it enables a side-by-side comparison of two
doctrines that fall under the umbrella of impermissible hindsight. Id.; Ex parte Lang, No. 2010000573 (B.P.A.I. Feb. 28, 2012).
282 In re Kotzab, 217 F.3d 1365, 1371–72 (Fed. Cir. 2000); In re Fritch, 972 F.2d 1260, 1266
(Fed. Cir. 1992); Application of Marshall, 578 F.2d 301, 304–05 (C.C.P.A. 1978); Application of
Rosenberger, 386 F.2d 1015, 1018 (C.C.P.A. 1967).
283 Ex parte Schweickhardt, No. 2010-005319, 2012 WL 760133, at *1 (B.P.A.I. Mar. 6, 2012).
284 Ex parte Field & Pouliot, No. 2009-015300, at *1 (B.P.A.I. Apr. 6, 2011).
285 Ex parte Thomas, No. 2009-011,263, 2009 WL 3127479, at *1 (B.P.A.I. Sept. 28, 2009).
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about 100ºC to about 150ºC to a
smooth form.”286
Ex parte Lind

“regions with different
coefficients of friction”287

Ex parte Gonzales

“adjustably movable . . . to
create a locking force.”288

Ex parte Bernaski

“minimize the amount of
workpiece coating bridging”289

Ex parte Gottis, No. 2001-0008, 2002 WL 31234500, at *1 (Jan. 16, 2002).
Ex parte Lind, No. 2003-0117, 2004 WL 77362, at *1 (B.P.A.I. July 9, 2003).
288 Ex parte Gonzales, No. 2010-006566, 2012 WL 1562605, at *1 (B.P.A.I. Apr. 30, 2012).
289 Ex parte Bernaski & Palmieri, No. 2011-006732, 2012 WL 2930138, at *1 (B.P.A.I. July 16,
2012).
286
287
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Ex parte Laude

“noise is common throughout
said
noise
susceptible
circuits”290

Ex parte Soika

“adapted to prevent removal of
said second end from said
recess”291

Ex parte Schnoebelen

“presents each uppermost said
sheet for . . . grasping between a
thumb and fingers”292

294

Ex parte Honma
“for thin film growth”293
Ex parte Bemis
“for automatically draining and
cleaning”294
Ex parte Kinross
“having a minimal coefficient of
friction
for
providing
operational advantages”295

F. The trap of Ex parte Hough and Ex parte Hovath.
The following discloses a trap that can result in the drafting of an inappropriate
rebuttal to rejection against a claim that has a functional element. By disclosing an
incorrect way to rebut the rejection, the following provides guidance for drafting
correct rebuttals. In Ex parte Hough the claim read as follows.

Ex parte Laude, No. 1999-1553, 2003 WL 21280019, at *1 (B.P.A.I. Sept. 24, 2001).
Ex parte Soika & Arich, No. 2010-002671, 2011 WL 4894095, at *1 (B.P.A.I. Sept. 28, 2011).
292 Ex parte Schnoebelen, Jr., No. 2012-000090, 2013 WL 663569, at *2 (P.T.A.B. Feb. 21,
2013).
293 Ex parte Honma & Arai, No. 2002-1640, 2003 WL 25283764, at *1 (B.P.A.I. Mar. 6, 2003)
294 Ex parte Bemis, No. 96-2270, 1996 WL 1749167, at *1 (B.P.A.I. Dec. 9, 1997).
295 Ex parte Kinross, No. 2010-001194, 2012 WL 1493776, at *1 (B.P.A.I. Apr. 26, 2012).
290
291
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[Claim] 1.
A cleaning apparatus . . . comprising . . . a first strip of
material . . . wherein the first strip will vertically compress when
drawn through a roller nip and partially vertically decompress
when exiting the roller nip.296
The associated structural element is “first strip.” 297 Please notice the existence
of a structure (“roller nip”) residing in the functional element. The examiner rejected
the claim in view of the Beeson prior art, and the Board affirmed this rejection. 298
The inventor fruitlessly argued that “there is no roller nip described [in Beeson] and
no vertical decompression beyond a nip for cleaning.” 299 In other words, the inventor
argued that Beeson does not disclose a roller nip, and that the fact that Beeson does
not disclose a roller nip mandates that Beeson cannot be invalidating prior art
against the claim.
The Board explained the correct role of functional elements in claims: “the claim
language does not positively recite a roller nip. Instead the claim defines a cleaning
apparatus for use in a paper handling device which includes a roller nip.”300
Where a functional element includes a short description of a laboratory test, and
where this description includes various devices or instruments, it must be realized
that the names of these devices and instruments do not have any patentable weight.
This trap should be avoided.
Ex parte Horvath discloses the same trap. The claim was as follows:
[Claim] 11. A pull bar screen system, comprising: a screen for retraction
into and extension from a cassette housing.301
The inventor argued that to invalidate the claim, the cited prior art (Tedeschi)
must disclose the cassette housing.302 Thus, the inventor argued, “Tedeschi utterly
fails to teach the claimed cassette housing.”303 But the inventor had fallen into a
trap. The Board refused the inventor’s argument, writing, “[w]e note that claim 11
does not recite the structure of a cassette housing, but rather claim 11 calls for the
screen to have the capability of being retracted into and extended out of a cassette
housing.”304 The Board affirmed the rejection.305 Ex parte Depuy Spine also
illustrates, “The Hough/Hovath Trap.” In this opinion, the inventor improperly
argued that a structure (“bone anchor”) residing in the functional element had
patentable weight.306

296

2009).

Ex parte Hough & Feshazion, No. 2009-002932, 2009 WL 2203090, at *1–2 (B.P.A.I. July 22,

Id. at *2.
Id. at *5–6.
299 Id. at *5; Appellant’s Brief, U.S. Patent Application No. 10/707,470, at 8 (Oct. 22, 2007).
300 Hough, 2009 WL 2203090, at *5.
301 Ex parte Horvath, No. 2009-007735, 2010 WL 4780590, at *1 (B.P.A.I. Nov. 18, 2010).
302 Id. at *5.
303 Id.
304 Id.
305 Id. at *6.
306 Ex parte Depuy Spine, Inc., No. 2009-1700, 2009 WL 887278, at *3–4 (B.P.A.I. Mar. 31,
2009).
297
298
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G. Inappropriate use a function of a prior art structure to invalidate a structural
element in a claim—the trap of In re Robertson.
The trap of Ex parte Hough and Ex parte Hovath, described above, reveals how a
structural element that is nested within a functional element does not have
patentable weight. The following reveals another trap, the trap of In re Robertson.
The trap of In re Robertson teaches that a function disclosed in the prior art, without
more, cannot anticipate a structural element in a claim.307
Where a claim element in question is a structural element, a prior art disclosure
of a function possessed by that structure is not likely to be relevant to that structural
element, where an adverse party’s goal is to invalidate the claim.
In re Robertson provides an exemplary fact-pattern. The claims to the
Robertson diaper were to a diaper having three fasteners. 308 The prior art Wilson
diaper was a diaper that had only two fasteners.309 In an earlier hearing before the
Board, the Board had held that the Wilson diaper was invalidating prior art
against the Robertson diaper, in view of the fact that the two fasteners of the
Wilson diaper could perform all of the same functions as the three fasteners of the
Robertson diaper.310
The case was appealed to the Federal Circuit, and the resulting opinion held
that the Board had wrongly decided the case. 311 The Federal Circuit held that even
though the two fasteners of the Wilson diaper could perform the same function as the
three-fastener diaper of Robertson, Wilson was not invalidating prior art. 312 The
take-home lesson is that the disclosure of a function in the cited prior art must not be
used to invalidate, by anticipation, a structural element in the claim under review,
where the adverse party alleges that the function constitutes a disclosure of that
structure.
IX. MALLEABILITY OF FUNCTIONAL ELEMENTS.
The meaning of any given functional element in a claim can be altered, during
prosecution, by amending the claim. Typically, where a functional element is
amended, it is amended to recite a narrower function. Where the goal, during
prosecution, is to narrow the scope of the functional element, the functional element
can be changed from one that is broader in scope to one that is narrower in scope.
Narrowing amendments are typically made to avoid the prior art. Narrowing
amendments are also made to confer enablement to a claim, where a claim element
otherwise would be too broad to be patentable.
Claim amendments are not permitted during an appeal, but the meaning of any
given functional element can be altered merely by way of arguments, for example, an
argument that the examiner’s understanding of a functional element was too broad,
In re Robertson, 169 F.3d 743, 745 (Fed. Cir. 1999).
Id. at 744.
309 Id.
310 Id. at 745.
311 Id. at 746.
312 Id. at 745.
307
308
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and that the true meaning of the functional element must conform to a definition
that is found in the specification. 313
“Malleability,” in this article, refers to claim amendments, and also to
arguments (without any amendment) that contend that a given functional element
should be interpreted to have a broader or a narrower meaning.
A. Malleability taking the form of amending the claim to replace a first functional
element with a second, narrower functional element.
In the file history of U.S. Pat. No. 7,241,865, the claim initially had a claim
reading:
said polypeptide is
differentiation.314

capable

of

inducing

chondrocyte

re-

The functional element is shown in bold.
The associated structure is,
“polypeptide.”315 But the patent examiner rejected the claim, alleging that the claim
was not enabled (35 USC § 112).316 The examiner alleged that the functional element
was complex, involved many factors, that the specification failed to provide guidance
on measuring chondrocyte re-differentiation, and that it would require undue
experimentation to measure chondrocyte re-differentiation.317 In response, the
applicant amended the functional element to a simpler form, where the simpler
functional element read:
said polypeptide is capable of inducing chondrocyte proliferation.318
The result was allowance of the claim. 319
The following concerns a different patent case, which also illustrates
malleability. In the file history of U.S. Pat. No. 6,927,056, the claim initially read:
An isolated polynucleotide encoding . . . a biologically active fragment of
a polypeptide that comprises the amino acid sequence depicted in SEQ ID
NO.1.320
In response to an indefiniteness rejection, the inventor amended the claim to
input a narrower functional element.321 The amended claim read as follows. The two
functional elements shown in bold:
Brody, Contexts of Implication, supra note 9, at *42–43.
Claims, U.S. Patent Application No. 10/363,937, at 2 (Mar. 4, 2003) (redrafted and
shortened from Claim 1 by the author).
315 Id.
316 Non-Final Rejection, U.S. Patent Application No. 10/448,923, at 3 (Mar. 27, 2006).
317 Id. at 4.
318 Amended Claims, U.S. Patent Application No. 10/448,923, at 3 (June 28, 2006).
319 U.S. Patent No. 7,241,865 col.650 l.27–29 (filed May 29, 2003).
320 Amendment, U.S. Patent Application No. 10/363,937, at 3 (Dec. 17, 2004).
313
314
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An isolated polynucleotide encoding . . . a biologically active fragment of
the polypeptide that consists of the amino acid sequence depicted in SEQ ID
NO: 1, wherein the fragment has cysteine protease activity.322
The result was allowance of the claim. 323
The Federal Circuit, in Monsanto Corp. v. Syngenta Seeds, Inc., has also
addressed the issue of functional elements that are overly broad, and that fail to
satisfy the enablement requirement (35 U.S.C. § 112).324
B. Malleability taking the form of amending the claim to include a functional element
where none previously existed.
The file history of U.S. Pat. No. 7,105,721 is representative of a fact pattern that
occurs in about half of all file histories of biotechnology patent applications. 325 This
situation is amending a claim to include a functional element where, prior to the
amendment, the claim did not contain a functional element. 326 In the file history of
U.S. Pat. No. 7,105,721, the inputted functional element was as follows:
“which is useful in antisense inhibition or sense suppression of endogenous
delta-12 desaturase activity in a transformed plant.”327
This functional element applied to the structural element “nucleic acid sequence
encoding a plant delta-12 desaturase.”328 Inputting a functional element by way of
an amendment, where no functional element had earlier resided in the claim,
represents a type of malleability. The amendment resulted in allowance of the
claim.329
C. Drawings as a basis for amending the functional element in a claim.
To amend a claim, a basis must be found elsewhere in the patent application for
the new language that is to be added by way of amendment. Typically, the newly
added language is imported from another claim in the claim set, or from the

321 Office Action, U.S. Patent Application No. 10/363,937, at 4 (Sept. 22, 2004). The examiner
contended that, “[s]aid definition renders Claim 1 indefinite as the scope of the functions
encompassed by the phrase ‘biologically active’ is not clear and, thus, one of skill in the art would
not know the metes and bounds of the invention.” Id.
322 U.S. Patent No. 6,927,056 col.191 l.2–9 (filed Sept. 6, 2001).
323 Id.
324 Monsanto Co. v. Syngenta Seeds, Inc., 503 F.3d 1352, 1361–62 (Fed. Cir. 2007).
325 Brody, Allowance of Genus Claims, supra note 6, at 648, Table 4A.
326 Id.
327 Amendment and Response to Final Office Action, U.S. Patent Application No. 10/108,795, at
4 (Apr. 5, 2005).
328 Id.
329 U.S. Patent No. 7,105,721 col.79 l.31–45 (filed Mar. 28, 2002).
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specification. Established case law330 holds that the language added to the claim
being amended does not have to match exactly the wording found in the other claim,
or found in the specification.
But what about deriving language, for an amendment, from a drawing that
resides in the specification? Drawings in patents usually do not contain any words at
all.
Ex parte Dart,331 Ex parte Almada,332 and Ex parte Lee333 disclose the situation
where an inventor successfully argued that a drawing served as a basis for new
language (structural element) inputted into a claim by way of an amendment. The
new language, in these three respective cases, was: “no smaller than a particular
size of about 40 microns,” “a ring diameter more than two times a ring width,” and, “a
drum connection duct positioned adjacent an exhaust outlet.”334
Functional
elements, when inputted into a claim by way of an amendment, can also find a basis
in a drawing, as illustrated by Ex parte Michelson.335 The functional element related
to the flexing function of a member, when the member contacts a tissue. 336 The
inventor successfully argued that the new language found a basis in the drawings, as
revealed by an excerpt from the Michelson opinion, revealed in the footnote.337
To conclude, when an attorney finds it necessary to amend the wording of a
functional element, a basis for this can be found in the specification, as well as in
drawings.

330 Purdue Pharma L.P. v. Faulding, Inc., 230 F.3d 1320, 1328 (Fed. Cir. 2000); Application of
Wertheim, 541 F.2d 257, 270 (C.C.P.A. 1976).
331 Ex parte Dart & Richmond, No. 2010-010812, 2011 WL 4545864, at *2–3 (B.P.A.I. Sept. 29,
2011).
332 Ex parte Almada, No. 2008-3862, 2009 WL 789939, at *5 (B.P.A.I. Mar. 23, 2009).
333 Ex parte Lee, No. 2009-003595, 2009 WL 2904632, at *6 (B.P.A.I. Sept. 9, 2009).
334 Id. at *3; Dart, 2011 WL 4545864, at *2; Almada, 2009 WL 789939, at *4.
335 Ex parte Michelson, No. 2009-009897, at 22 (B.P.A.I. Dec. 9, 2009).
336 Id. at 21–22.
337 Id. at 21. The Board stated:

The Examiner responded that the requirement the flexible member is at least in part
curved or concave when in contact with the tissue ‘does not further limit the structure of
the rivet itself’ because Appellant is basing patentability on one specific intended use
and one specific location when the device is not limited to use in one specific situation.
We disagree with the Examiner’s claim interpretation. Each of the above-identified
claims contains language requiring the flexible member to be at least in part curved or
concave when said flexible member is in contact with the tissue. This language imparts a
structural limitation on the rivet in that it requires that the rivet has a flexible member
that is made of a material and in a configuration that renders it capable of conforming to
the tissue and, in particular, that renders it capable of assuming a specific shape when
in contact with the tissue.
Id. (internal citation omitted) (emphasis in original).
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D. Malleability taking the form of alternate interpretations of one term.
In Ex parte Bree, the issue was the breadth of the meaning of the claim term
“hold.”338 The claim was as follows:
[Claim] 7. A locking actuator system . . . comprising . . . the combination of
the link, slot, extending pin, worm gear and worm hold the manual
locking lever in the locked position so that external force on the
manual locking lever does not move the manual locking lever.339
The examiner’s interpretation of the meaning of the word “hold” was such that
the lever could move or wiggle when held in the locking position. 340 This
interpretation permitted the examiner to impose a rejection in view of the prior
art.341 But the inventor’s interpretation of the word “hold” was narrower. 342 This
interpretation was that wiggling cannot occur at all. 343 The Board preferred the
narrow interpretation of the functional word, “hold.” 344 Thus, the inventor’s
argument was a success.345
To conclude, where it is necessary to amend a claim to narrow the scope of a
functional element, the attorney or agent should first contemplate whether it is
possible to narrow the scope merely by arguing that the definition understood by a
person reading the patent’s specification is narrower than the definition understood
by the examiner.
X. WEIGHT OF A FUNCTIONAL ELEMENT.
Claim elements of questionable weight fall into the established categories of:


Recitations of intended use;



Recitations of a workpiece; and



Recitation of instructions, numbers, or a database.

Although the first two of these are bona fide functional elements, they are
typically dismissed by patent examiners, and sometimes by the Board, as having no
patentable weight. Recitations of instructions, numbers, or of a database, are rarely
or almost never given patentable weight.346
Ex parte Bree, No. 1996-1300, 1996 WL 33140801, at *3 (B.P.A.I. Apr. 9, 2001).
Id. at *1–2.
340 Id. at *2.
341 Id.
342 Id. at *3.
343 Id. at *4.
344 Id.
345 Id.
346 Ex parte Aikens, No. 2009-006565, 2011 WL 4975869, at *5–6 (B.P.A.I. Oct. 14, 2011); Ex
parte Filippo, No. 2009-004068, at 14–15 (Apr. 13, 2010); In re Gulack, 703 F.2d 1381, 1386–87 (Fed.
338
339
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On occasion, cases from the Board dismiss functional elements, per se, as not
having patentable weight—that is, as being merely an “intended use” with no ability
to shield the patent from the invalidating effects of the prior art. Even though
functional elements are almost universally used in all technologies, the patentable
weight of this type of element continues to be inappropriately questioned in
contemporary opinions from the Board. The rudest treatment of functional elements
comes from In re Fuetterer. The Fuetterer opinion went so far as to contemplate (but
reject) the possibility that functional language is “expressly condemned by the patent
statutes,” and that the possibility that there is a “statutory ban on the use
of . . . ‘functional’ language.”347
Recitations of instructions, numbers, or databases do not constitute functional
elements, but are mentioned here in order to provide perspective on the issue of what
is and what is not a functional element. The best perspective of “patentable weight”
can be provided by describing a functional element that is truly weightless, as shown
below. “Weightless” means that the element is not capable of distinguishing the
invention, as claimed, from the prior art.
A. Example of functional element that truly lacks patentable weight.
As a reference point in this article, Ex parte Lee provides a functional element
that truly lacks weight.348 This functional element was the word “pharmaceutical,”
as it occurred in the term, “pharmaceutical composition.”349 The inventor tried to
distinguish the claimed composition from the prior art by arguing that
“pharmaceutical” requires sterility and requires that the composition be free of
toxins.350 The inventor provided a reasonable and clever argument, in an effort to
distance his claimed drug (erythropoietin-binding protein) from the compound
disclosed by the Lee prior art. 351 In short, the inventor pointed out that in Lee, the
erythropoietin-binding protein was injected into experimental animals in a form that
contained toxins (blue dye and polyacrylamide). 352 However, the Board refused this
argument primarily on the basis that the specification failed to define
“pharmaceutical” as requiring sterility and freedom from toxins.353 This author also
points out that the term “pharmaceutical” cannot mean sterility and cannot exclude
toxins, because pharmaceuticals that are vaccines often include live bacteria, and
pharmaceuticals that are anti-cancer agents are usually toxins.354 Terms such as
Cir. 1983); Ex parte Jaehn, No. 2009-010768, at 13–14 (B.P.A.I. Nov. 24, 2009); Ex parte Kurz &
Reinschke, No. 2009-006519, 2010 WL 3198430 (B.P.A.I. Aug. 9, 2010); Ex parte Lewis, No. 2009003285, 2009 WL 4062365, at *6 (B.P.A.I. Nov. 20, 2009); Ex parte Nehls, No. 2007-1823, 2008 WL
258370, at *4–5 (B.P.A.I. Jan. 28, 2008); In re Ngai & Lin, 367 F.3d 1336, 1339 (Fed. Cir. 2004).
347 Application of Fuetterer, 319 F.2d 259, 262, 265 (C.C.P.A. 1963).
348 Ex parte Lee, No. 2010-007770, 2011 WL 109121, at *2 (B.P.A.I. Jan. 11, 2011).
349 Id. at *1.
350 Id. at *2.
351 Id.
352 Id.
353 Id. at *3.
354 William R., Toxicity and Antitumor Effect of Divided Doses of Methotrexate, 115 ARCHIVES
INTERNAL MED. 285, 285 (1965); Peter H. Wiernik, Phase I Clinical and Pharmacokinetic Study of
Taxol, 47 CANCER RES. 2486, 2486 (1987).

[13:251 2014] The John Marshall Review of Intellectual Property Law

302

“pharmaceutical composition” or “formulation” can distinguish a composition from
the prior art, where the composition in the prior art is generated inside the body (and
does not occur in a form that can possibly be administered to a patient). In this case,
“pharmaceutical composition” and “formulation” are negative claim limitations,
because they exclude certain embodiments, that is, they exclude embodiments that
occur inside the body.
Another quasi-functional element is “naturally occurring.”
Ex parte Lal
concerned a claim that read as follows. The quasi-functional element is shown in
bold:
An isolated polynucleotide encoding . . . a polypeptide comprising a
naturally occurring amino acid sequence at least 90% identical to the
amino acid [sequence] of SEQ ID NO:1.355
The claim was rejected for lack of enablement (35 U.S.C. § 112), because the
claimed polynucleotide encompassed many polynucleotides that possessed no
particular function.356 Please note that the claim element “naturally occurring” does
not imply, suggest, or require any biological function. To provide a concrete example,
the skilled artisan will readily understand that “naturally occurring” glucose is
exactly the same, in structure and in functional capabilities, as synthetic glucose.
Ex parte Lee and Ex parte Lal provide a reference point, or perspective, for
assessing all other opinions described in this article, that is, by disclosing the concept
of functional elements that truly lack any patentable weight.
B. Cases where both the examiner and the Board improperly dismissed recitation of
intended use.
Ex parte Warner illustrates the fact pattern where the Board dismissed the
intended use element, without taking the following into consideration.357 The Board
failed to consider the argument that the cited prior art was not capable of that
intended use. Also, the Board failed to consider the argument that the recitation of
intended use could distinguish the claim from the prior art. The claim was as
follows, where the intended use is shown in bold.
[Claim] 1. A device for opening a frozen or stiff seal formed between a door
and a door frame, said device comprising . . . plate portions . . . the device
pivots about the central point . . . and force the car door away from an
adjacent relationship with the door frame so as to separate and break the
frozen or stiff seal formed between the door and the door frame.358

Ex parte Lal, No. 2006-1035, 2006 WL 2710996, at *1 (B.P.A.I. Sept. 18, 2006).
Id. at *2.
357 Ex parte Warner, 2006-1748, 2006 WL 2524303, at *2, *3 (B.P.A.I. Aug. 29, 2006).
358 Appeal Brief, U.S. Patent Application No. 10/728,375, at 11–12 (May 19, 2005) [hereinafter
10/728,375 Appeal Brief].
355
356
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The examiner rejected the claim, writing that the “limitations regarding the use
of the device on a frozen door are merely considered to be intended use of the device
and are not accorded patentable weight.” 359 The inventor did, in fact, argue that the
cited prior art (Sutton) was not able to separate and break a frozen or stiff seal,
writing that “the device disclosed in Sutton would be ill-suited for opening frozen
doors . . . as the plastic construction [of Sutton] may break as the user attempts to
lever the door open.”360
But the Board similarly dismissed the intended use element, writing, “we agree
with the examiner that this language pertains to the intended use of the device. . . . A
statement of intended use does not qualify or distinguish the structural apparatus
claimed over the reference.
C. Cases where examiner dismissed recitation of intended use, but the Board properly
assessed the patentable weight of the intended use.
The cited cases document most or all of the cases, to date, where a claim element
that recited an “intended use” was dismissed by the examiner, but was properly
construed by the Board where the patentable weight was properly assessed.361
The following discloses a typical fact pattern where a functional element is
dismissed by the examiner as having no patentable weight, and where the Board
properly assesses the weight.
Ex parte Takahashi properly stated that “intended use” can lend patentable
weight to a claim, where the appropriate approach to claim construction is to
determine if the prior art apparatus is capable of performing the intended use. 362 In
other words, if the prior art cannot perform the intended use, the claim element has
prevented the prior art from invalidating the claim. Although the following wording
was crafted to address the facts of the case, the Board’s words express the general
approach to claim construction. The Board wrote that, “the prior art structure meets
the claims because the prior art apparatus is capable of performing the intended
use.”363

Office Action, U.S. Patent Application No. 10/728,375, at 2 (June 10, 2004).
10/728,375 Appeal Brief, supra note 358, at 5.
361 Ex parte Stengelin & Baaser, No. 2011-004953, 2012 WL 3720951, at *2–3 (B.P.A.I. Aug. 27,
2012); Ex parte Betzold & Busacker, No. 2011-011011, 2012 WL 3801747, at *8 (Aug. 28, 2012); Ex
parte Kent, No. 2010-008673, 2012 WL 3863265, at *4 (B.P.A.I. Aug. 31, 2012); Ex parte Quickie,
LLC, No. 2012-000944, 2012 WL 2316828, at *3–4 (B.P.A.I. June 15, 2012); Ex parte Otis, No. 2009007406, 2010 WL 4340271, at *2 (B.P.A.I. Nov. 1, 2010); Ex parte Kamihara, No. 2010-010642, 2012
WL 1071539, at *2 (B.P.A.I. Mar. 27, 2012); Ex parte Hosoito & Okazaki, No. 2010-005212, 2012 WL
889723, at *2–3 (B.P.A.I. Mar. 7, 2012); Ex parte Cronley, No. 2009-012643, 2011 WL 2621058, at *3
(B.P.A.I. June 30, 2011); Ex parte Ochiai & Ozawa, No. 2010-000856, 2012 WL 2356530, at *2–3
(B.P.A.I. June 12, 2012); Ex parte Kraft, No. 2010-003586, 2011 WL 2168571, at *2, *3 (B.P.A.I. May
26, 2011); Ex parte Mudge, No. 2010-011847, 2010 WL 4670640, at *4–5 (B.P.A.I. Nov. 16, 2010); Ex
parte Bemis, No. 96-2270, 1996 WL 1749167, at *1–3 (B.P.A.I. Dec. 10, 1997); Ex parte Baiges, No.
2005-1273, 2005 WL 4773323, at *2–3 (B.P.A.I. July 18, 2005); Ex parte Schnoebelen, Jr., No. 2012000090, 2013 WL 663569, at *2–3 (P.T.A.B. Feb. 21, 2013).
362 Takahashi, 2004 WL 2733658, at *2.
363 Id.
359
360
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Similarly, in Ex parte Jochum, the examiner refused to consider the patentable
weight of the functional element:
with the proviso that said composition is suitable for preparing a temporary
dental restorative material.364
The examiner’s rationale was that this element was merely a recitation of
“intended use.”365 The Board reversed the rejection, holding that the functional
element describes “indispensable characteristics that must be present in the
monomeric components required by the claimed invention.” 366
In Ex parte Kormann, the functional element was as follows:
with the proviso that the relaxivities of the contrast media are such that r 1
is greater than 9 x 104 M-1s-1.”367
In imposing an anticipation rejection, the examiner, in effect, dismissed the
weight of the functional element, writing that the cited prior art are “presumed” to
contain all of the functional elements.368 In imposing an obviousness rejection, the
examiner also, in effect, dismissed the weight of the functional element, writing that
“it would have been obvious to those of ordinary skill in the art that minor variations
in the relaxivity . . . could be made.”369
The Board reversed both rejections,
demonstrating that functional elements have bona fide patentable weight, and also
demonstrating the proper burden for alleging anticipation and obviousness. 370
D. Claim construction that uses a strawman.
Several opinions from the Board use a “strawman” approach for claim
construction. In this approach, the Board first dismissed recitations of intended use
as having no patentable weight. Then, the Board proceeded to assess the patentable
weight of the recitation of intended use.
The strawman approach to claim
construction was used in Ex parte Jung. The opinion initially wrote that “[t]he mere
recitation of an intended use in a claim will not be given any patentable weight,”
citing In re Dense.371 But immediately after this, the opinion analyzed the patentable
weight of the functional element, writing, “[n]otwithstanding the proscription against
giving patentable weight to statements of intended use,” and then held that the
functional element distinguished the claim from the prior art. 372 Thus, by its own
admission, the Board takes the “strawman” approach to claim construction. In the
Ex parte Jochum, No. 95-1999, 1999 WL 33161329, at *2 (B.P.A.I. Feb. 8, 1999).
Id.
366 Id.
367 Ex parte Kormann, No. 1997-2199, 2001 WL 816644, at *1 (B.P.A.I. June 27, 2000).
368 Id. at *2.
369 Id.
370 Id. at *2, *3.
371 Ex parte Jung, No. 2009-014528, 2010 WL 1725741, at *9 (B.P.A.I. Apr. 27, 2010);
Application of Dense, 156 F.2d 76, 77 (C.C.P.A. 1946).
372 Jung, 2010 WL 1725741, at *9.
364
365
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strawman approach, the Board cites case law that it never intends to use, and then
proceeds to ignore that case law.
Other cases using the strawman approach are cited.373 This author suggests
that the Board refrain from using the strawman approach to claim construction. The
strawman approach, which is based on archaic case law such as In re Sinex,374 In re
Casey,375 and In re Dense,376 is counterproductive.
E. Summary and conclusions.
To conclude, where an examiner or the Board dismisses a functional element as
“intended use,” the inventor’s first goal should be to argue that the recitation of
intended use is a genuine functional element. The inventor’s next goals are to argue
using one or more of the following approaches:


The cited prior art fails to expressly disclose the function of that
functional element;



The cited prior art is not capable of performing the same function as
that identified in the functional element;



The cited prior art performs a function that is opposite that which is
required by the claim’s functional element;



The functional element in the claim confers upon the corresponding
structural element (in the same claim) a specific type of structure,
where this type of structure is not disclosed by the cited prior art
reference. For example, the specific type of structure can be
constrained by a certain shape, dimension, chemical composition, or
relation to other structural elements in the same claim.
F. Workpiece.

“Workpiece” is a category of claim element that is typically found to have no
patentable weight. Where a claim identifies a workpiece, the claimed device is
described in terms of its relationship with the workpiece, or with a particular
environment of use. The workpiece and environment of use have a firmly established
role in determining the structures of the structural elements in a claim, according to
373 Ex parte Su & Lin, No. 2010-005722, 2012 WL 3903368, at *5 (B.P.A.I. Aug. 31, 2012); Ex
parte Henninger III & Bolotine, No. 2010-010605, 2012 WL 5975825, at *8 (P.T.A.B. Nov. 26, 2012);
Ex parte Ignatiev, No. 2009-011747, 2010 WL 1188327, at *4 (B.P.A.I. Mar. 25, 2010); Ex parte
Denvir, No. 2009-014463, 2010 WL 3803765, at *4 (B.P.A.I. Sept. 24, 2010); Ex parte Addington, No.
2008-0915, 2008 WL 3874418, at *4 (B.P.A.I. Aug. 19, 2008); Ex parte Honma & Arai, No. 20021640, 2003 WL 25283764, at *4 (Mar. 6, 2003).
374 Application of Sinex, 309 F.2d 488, 492 (C.C.P.A. 1962).
375 Application of Casey, 370 F.2d 576, 580 (C.C.P.A. 1967).
376 Dense, 156 F.2d at 77.

[13:251 2014] The John Marshall Review of Intellectual Property Law

306

Ex parte Nelson.377 The Ex parte Nelson opinion admits to the “tremendous difficulty
in making sense of apparatus claims whose structure depends on the environment of
use.”378
The following discloses the workpieces in various claims. Ex parte Crenshaw
concerned a claim to a fly swatter, where the workpiece was a fly.379 Ex parte
Manser concerned a claim to a treadmill, where the workpiece was a person’s
foot.380 Ex parte Faye claimed a device that was a fuel cell, where the workpiece
identified in the claim was hydrogen.381 Ex parte Khan claimed a conduit where the
workpiece was vapor.382 In Ex parte Bogatyrev, the claimed structure was “an
element for arranging,” and the workpiece was stacks of bank notes.383
The inventors were not interested in making, using, or selling flies, human feet,
hydrogen, vapor, or stacks of bank notes. These recitations were workpieces which,
in a properly drafted claim set, serve the purpose of conferring a particular range of
structures on the claimed device, for example, a device that is a fly swatter, a device
that is a treadmill, a device that is a fuel cell, or an element for arranging,
respectfully.
Often, the Board dismisses a recitation of a workpiece as having no patentable
weight. For example, Ex parte Bergdoll dismissed workpieces in this way.384 A
number of cases from the Federal Circuit and Court of Customs and Patent Appeals
also dismiss workpieces, as identified in the footnote.385
In contrast, in the following cases, the Board considered the possibility that the
recitation of a workpiece conferred patentability to the claimed device.386
Where the examiner or Board fails to assess patentable weight of a “workpiece,”
the attorney or agent should explore the possibility that the workpiece does confer
one or more of the following things:

377

2007).



A specific range of structures or dimensions to any particular
structural element;



A specific range of chemical compositions to any particular
structural element; or

Ex parte Nelson & Anderson, No. 2007-2914, 2007 WL 4162768, at *5 n.2 (B.P.A.I. Nov. 21,

Id.
Ex parte Crenshaw, No. 2008-4083, 2008 WL 6678100, at *1 (B.P.A.I. Nov. 18, 2008).
380 Ex parte Manser, No. 2009-005349, 2010 WL 896634, at *1 (B.P.A.I. Mar. 11, 2010).
381 Ex parte Faye, No. 2007-2553, 2007 WL 2211385, at *1 (B.P.A.I. July 31, 2007).
382 Ex parte Khan, No. 2009-004390, 2009 WL 2760731, at *1 (B.P.A.I. Aug. 28, 2009).
383 Ex parte Bogatyrev, No. 2009-002185, 2009 WL 1719562, at *1 (B.P.A.I. June 12, 2009).
384 Ex parte Bergdoll, No. 2009-011825, 2011 WL 1100038, at *3 (B.P.A.I. Mar. 23, 2011).
385 Application of Otto, 312 F.2d 937, 941 (C.C.P.A. 1963); Application of Rishoi, 197 F.2d 342,
345 (C.C.P.A. 1952); In re Young, 75 F.2d 996, 998 (C.C.P.A. 1935); In re Smith, 36 F.2d 302, 303
(C.C.P.A. 1929).
386 Ex parte Maeda, No. 2009-011173, 2010 WL 2070573, at *3–4 (B.P.A.I. May 21, 2010); Ex
parte Farris, No. 2004-1945, 2004 WL 4983402, at *3–4 (B.P.A.I. Sept. 15, 2004); Khan, 2009 WL
2760731, at *9; Ex parte Porro & Sauer, No. 2008-0184, 2008 WL 2259960, at *5–6 (B.P.A.I. Mar. 11,
2008).
378
379
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Any particular relationship between two different structural
elements in the same claim.

If the workpiece does, in fact, confer one or more of these things, then the
attorney or agent should argue that the workpiece has patentable weight.
XI. FUNCTIONAL ELEMENTS IN BIOTECHNOLOGY.
The following concerns functional elements in biotechnology claims, that is,
claims that encompass nucleic acids, polypeptides, or antibodies.
A. Biotechnology claims to nucleic acid sequences and polypeptides.
Ex parte Porro concerned the need for a representative number of species, in the
specification, to support a genus claim. The claimed genus was set forth by the
language:
encoding L-galactose dehydrogenase (LGDH) enzyme having at least about
90% identity to SEQ ID NO: 11.387
The term “L-galactose dehydrogenase” was the functional element. “LGDH”
means “L-galactose dehydrogenase.”388 But more accurately, this term performs
double duty by identifying the catalytic activity (catalytic activity is a function, not
an object) that is required by each and every one of the species that are encompassed
by the claim, and also by identifying the genus of enzymes (an enzyme is an object,
not a function) that are able to catalyze that function. The term “at least about 90%”
identifies breadth of the genus.389
The Board required a disclosure in the
specification of a representative number of species of nucleic acids, where the
purpose of this representative number was to satisfy the requirements for patenting
a genus of nucleic acids.390
The Board expressly found that the claim was valid under the requirement for
enablement (35 U.S.C. § 112), writing, “[g]ranted, those skilled in the art could make
libraries of SEQ ID NO: 11 variants and screen them . . . and that have LGDH
enzymatic activity.”391 Ex parte Porro reveals that functional elements are central to
assessing the enablement requirement. Thus, it was the case that the specification
disclosed an adequate number of species for supporting the claimed genus, and it was
the case that the functional element in the claim adequately defined the scope of the
claimed genus.
An appropriate counterpoint to Ex parte Porro is provided by a case from the
Federal Circuit, where the functional element (“sequence which functions in plant
Porro, 2008 WL 2259960, at *1.
Id.
389 Id.
390 Id. at *5.
391 Id. at *4.
387
388
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cells”) was held to be too broad, and therefore not enabled. 392 Because the functional
element was not enabled, the court rendered the claim invalid under 35 U.S.C.
§ 112.393
Comprehensive guidance for using functional elements to support broad genus
claims are provided by the cited article.394 In particular, this article demonstrates
how functional elements ensure satisfaction of the enablement requirement by the
genus claim.
B. Biotechnology claims to antibodies.
Where the functional element requires binding of an antibody to a polypeptide,
the written description requirement only needs the specification to disclose the amino
acid sequence of the entire polypeptide. As illustrated by the following opinion, there
is no need to identify the actual specific target epitope within that polypeptide.
Ex parte Dickson concerned a claim to an antibody, where the claim contained a
typical functional element (typical to claims to antibodies) requiring binding of the
antibody to a specific target protein.395 The functional element was, in effect, “which
selectively binds to . . . matriptase.”396 The term “matriptase” is the name of a
protein that is the antibody’s target. The claim identified the antibody’s target by the
target’s trivial name (not by the chemical structure of the target).397 But this lack of
detail was not the issue. The issue was that the examiner had rejected the claim
under 35 U.S.C. § 112, alleging that the specification did not have sufficient written
description.398 The examiner believed that the detail that was required in the
specification was the structural epitope of the target protein.399 Please see the
footnote for scientific background.400 The Board reversed the rejection under 35
U.S.C. § 112, and held the claim to be valid. 401 Thus, the Board held that validity of
the claim only required that the specification identify the amino acid sequence of
matriptase (and that there was no requirement to identify the epitope that resided in
matriptase).402
Monsanto Co. v. Syngenta Seeds, Inc., 503 F.3d 1352, 1361, 1362 (Fed. Cir. 2007).
Id. at 1362.
394 Brody, Allowance of Genus Claims, supra note 6, at 623.
395 Ex parte Dickson, No. 2007-4125, 2007 WL 5108541, at *1 (B.P.A.I. Nov. 5, 2007).
396 Id.
397 Id.
398 Id.
399 Id. at *3.
400 Susan Zolla-Pazner, Identifying Epitopes of HIV-1 that Induce Protective Antibodies, 4
NATURE REV. IMMUNOLOGY 199, 199 (2004). Antibodies are proteins. Antibodies contain a region
configured for specifically binding to a target. The target can be, for example, a particular protein of
an infecting organism such as hepatitis C virus or Salmonella bacterium. When the antibody binds
to a particular protein, it is never the case that the antibody binds to all regions of the protein.
Instead, it is the case that the antibody binds to a specific part of the protein, called an “epitope.”
Epitopes occupy a small proportion of the exposed surface of the target protein, perhaps a few
percent of the exposed surface. While the amino acid sequence of any given protein is very easy to
determine, it is extremely difficult to determine or identify an epitope that is bound by any given
antibody.
401 Dickson, 2007 WL 5108541, at *4.
402 Id.
392
393
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To view the big picture, functional elements in antibody claims almost always
take the form of a recitation that the claimed genus of antibodies must be capable of
binding to a specific target.403
C. Disclosure of laboratory tests for the functional element.
The following cases disclose the value of including, in the specification, a short
description of laboratory tests that correspond to each functional element in a claim.
Ex parte Adler provides a powerful and universal lesson, regarding the
enablement requirement (35 U.S.C. § 112). The examiner rejected the genus claim
for lack of enablement.404 But the Board reversed, in view of the fact that the
specification disclosed a screening assay that is sensitive for variants, within the
claimed genus, that possess the biochemical activity of binding a bitter ligand.405
Ex parte Abad provides the same take-home lesson. Ex parte Abad concerned a
genus claim with the functional element, “which is pesticidal for at least one pest
belonging to the order Coleoptera.”406 This function was required for each and every
one of the species of nucleic acid variants that fell under the umbrella of the genus
claim.407 The Board held that the enablement requirement for the claimed genus was
satisfied, in view of the fact that the specification disclosed a screening test that
detected pesticidal activity of each variant protein, an identification of a conserved
domain, as well as several species of working examples of variant proteins. 408 The
Board wrote that the screening test allowed scientists to conduct routine screening
for discovering working species that belonged to the genus. 409
A related topic is rejections under 35 U.S.C. § 112, for lack of written
description. Ex parte Rollat-Corvol discloses the fact pattern where the compositions
in the claim consisted in a less detailed structural element and a more detailed
functional element.410 For example, the claim required a “tacky polymer having a
glass transition temperature (Tg) of less than 20ºC.”411 The examiner rejected the
claim, alleging that “the specification provides no written description as to what the
structural characteristics of a polymer would be required to meet all the functional
limitations.”412

Brody, Allowance of Genus Claims, supra note 6, at 651–52.
Ex parte Adler, No. 2006-0157, at 5 (B.P.A.I. Mar. 23, 2006).
405 Id. at 5–6.
406 Ex parte Abad, No. 2007-4213, 2008 WL 904456, at *1 (B.P.A.I. Apr. 3, 2008).
407 Id. at *2–3.
408 Id. at *8.
409 Id. at *12.
410 Ex parte Rollat-Corvol & Samain, No. 2009-003513, at 2 (B.P.A.I. Nov. 2, 2009).
411 Id.
The author notes that “tacky” and “temperature (Tg) of less than 20ºC” represent
functional elements, while “polymer” represents a structural element.
412 Id. at 3. Fortunately for the inventor, the Board explored the specification and detected a
sufficient quantity of structural characteristics, and reversed the rejection.
403
404
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XII. DISCLOSURES THAT MAY BE INCLUDED IN THE SPECIFICATION FOR DEFENDING
AGAINST PRIOR ART REJECTIONS.
The following reveals disclosures, drafted into the specification, that can be of
potential use in defending a functional element from prior art rejections.
A. Defending a claim’s functional element by including a disclosure of laboratory test
results in the specification.
Where an attorney or agent representing a client has a claim set in hand, a prior
art search should be conducted. The goal of the prior art search is to identify devices
or compositions that are likely to have the same function as that required by the
functional element. Once these devices or compositions are identified, the inventor
should conduct a side-by-side laboratory experiment to determine if the functions are
the same or different. The side-by-side experiment should be designed to compare
the preferred embodiment of the inventor, and the closest possible embodiment of the
device that is disclosed by the prior art. Where the results of this experiment are
available, the attorney or agent will more easily be able to rebut rejections against
the claim.
Ex parte Dieu concerned an invention that was a photomask. 413 The cited prior
art was Liang.414 The Board believed that the cited prior art was capable of the same
function and, on the basis of this belief, rejected the claim. 415 The court proclaimed
that inventors,
who are in a better position than the PTO to test the operable capabilities
of the photomask of Liang, including the capabilities of the buffer layer
materials, have not proven that the buffer layer materials described by
Liang for use in their photomask do not have the argued characteristics as
called for in . . . claim 21.416
This opinion provides a distinct take-home lesson for all inventors. Inventors
need to be ready and willing, preferably before filing the patent application, to
conduct side-by-side tests that compare their invention with the device or
composition of competitors that is closest to the invention.

413

2011).

Ex parte Dieu & Lamantia, No. 2009-005807, 2011 WL 1100035, at *1 (B.P.A.I. Mar. 23,

Id.
Id. at *3.
416 Id.
414
415
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B. Defending a claim’s functional element by examples in the specification that bracket
the function of the functional element.
Ex parte Koele provides a technique for resisting inherency-based rejections
against a claim that contains a functional element.417 This technique is to draft your
specification so that it discloses a few structures (or devices or compositions) that are
capable of performing that function, but also to disclose or identify some structures
that cannot perform that function.
Ex parte Koele teaches that inventors should draft patent applications to include
parameters that are encompassed by the claim’s functional element, as it applies to
the preferred embodiment, but also to document parameters that are outside of any
preferred embodiment, and that are outside of the umbrella of what is claimed.
Ex parte Koele documents a good patent-drafting technique, where the patent
documented parameters that were encompassed by the claim’s functional element, as
well as parameters outside the claim’s functional element. The following concerns
functional elements that take the form of a characteristic of a material, such as
whether the material is made of ceramic, plastic, or metal.
The relevant
characteristics of the material may also include, for example, torsion, strain,
conductivity, roughness or smoothness, surface friction coefficient, or hydrophobicity.
Ex parte Koele concerned a claim to diapers for infants. 418 The diapers included
a laminated material.419 The claim was as follows.
[Claim] 1. An absorbent article . . . comprising . . . outercover comprising a
laminated material including first and second-layers . . . wherein the
laminated material exhibits a Poisson’s ratio less than 1.0 at 4
percent longitudinal strain.420
The prior art cited against the claim was LeMahieu. 421 It was argued that
LeMahieu described a laminated material having the same function as that described
in the claim’s functional element.422 The inventor took the following tactic in arguing
that the LeMahieu laminate does not necessarily (does not inherently) possess the
same function.423 The inventor pointed out that there do exist similar laminates with
functional properties that are outside the range identified in the claim. 424
The inventor’s own patent application did identify a particular laminate that
had a Poisson’s ratio of more than 1.0 to 4 percent longitudinal strain. 425 This
argument proved successful in the inventor’s argument that the LeMahieu reference
did not necessarily possess the function in question.426

Ex parte Koele, No. 2009-013675, 2010 WL 2447925, at *2 (B.P.A.I. June 16, 2010).
Id. at *1.
419 Id.
420 Id.
421 Id.
422 Id.
423 Id.
424 Id.
425 Id.
426 Id. at *1, *2.
417
418
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The take-home lesson is that attorneys and agents using a functional element in
a claim should draft the patent’s specification to identify one or more structures that
fall under the umbrella of that functional element, and also one or more similar
structures that possess a similar function, but where the parameters of that function
all outside that of the element in the claim. Ex parte Rotach provides the same type
of take-home lesson.427
XIII. INDEFINITENESS.
The following identifies various indefiniteness issues that can inflict claims that
contain a functional element. In addressing the issue of indefiniteness in functional
elements, the Federal Circuit found that any ambiguity depends on the context, for
example, the disclosure in the specification and the knowledge of the skilled
artisan.428 Also, the Federal Circuit provided the advice that potential ambiguity can
be reduced “if the specification provided a formula for calculating a property along
with examples that meet the claim limitation [the functional element] and examples
that do not.”429 Specialized topics on indefiniteness, as provided by cases from the
Board, are as follows.
A. The Newman Paradox of functional elements.
Ex parte Newman illustrates a paradox that can occur when a claim is rejected
for indefiniteness (35 U.S.C. § 112), where the rejection alleged that the wording of a
functional element is ambiguous or indefinite.430 The author hereby names this the
Newman Paradox, because Ex parte Newman may be the best example of this
particular contradiction.431 The situation can be classed as a paradox, because the
claim language in question can render a claim less valid, but also render a claim
more valid. In detail, the claim language can render the claim invalid for
indefiniteness, but render the claim more resistant to prior art rejections (35 U.S.C.
§ 102; 35 U.S.C. § 103).432 By altering the language to make it less ambiguous, what

Ex parte Rotach, No. 2007-4414, 2008 WL 1834818, at *7 (B.P.A.I. Apr. 24, 2008).
Halliburton Energy Servs., Inc. v. M-I LLC, 514 F.3d 1244, 1253–54 (Fed. Cir. 2008).
429 Halliburton, 514 F.3d at 1256.
430 Ex parte Newman & Praechter, No. 1998-0408, 2002 WL 851849, at *1 (B.P.A.I. Feb. 22,
2001).
431 Brody, Obviousness in Patents, supra note 12, at 56. This author previously discovered and
documented another paradox in patent law, which is presently named the Wands-Vaeck Paradox.
The Wands-Vaeck Paradox is named after the standard for predictability needed to establish
enablement (35 U.S.C. § 112), as set forth by In re Wands, and by the standard for predictability
needed to reject a claim for obviousness (35 U.S.C. § 103), as set forth by In re Vaeck. In re Wands,
858 F.2d 731, 737 (Fed. Cir. 1988); In re Vaeck, 947 F.2d 488, 493 (Fed. Cir. 1991). The fact-pattern
is a paradox, because language that renders a claim more resistant to an enablement rejection at
the same time renders the claim more susceptible to an obviousness rejection (and vice versa).
432 Newman, 2002 WL 851849, at *4.
427
428
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happens is that the claim becomes more resistant to prior art rejections. 433 The
Court of Customs and Patent Appeals, in Application of David W. Wilson, commented
on the choice between rejecting a claim for obviousness or for indefiniteness, and in
dicta stated that if the claim was indefinite, the subject matter cannot be rendered
invalid under 35 U.S.C. § 103.434 However, this particular dictum did not concern
functional elements.
Claim 1 of Newman’s patent application contained the following functional
element. The associated structure is “an elongated strip”:
which is tear resistant but will tear completely if subjected to a
force which would jeopardize the safety of the wearer in an
amusement park environment.435
The Board rejected the claim for indefiniteness. 436 This rejection was based on
the fact that it was not clear what was the minimum amount of force needed to tear
the strip, and it was not clear what was the standard of safety.437
A paradox materialized. The examiner had cited a prior art reference (Melin)
against the claim, alleging that Melin disclosed a tear-resistant strip with the same
properties.438 But the Board reversed the prior art rejection, because it determined
that the degree of tear resistance of Melin could not be compared with the degree of
tear resistance required by the claim. 439 In the Board’s words, “it is impossible to
determine with any certainty whether the tear resistant glass fibre-reinforced paper
of Melin . . . inherently possesses the degree of tear resistance required by these
claims.”440 In other words, the Board held that the ambiguity of the claim was so
extreme, that the claim defied validity analysis under 35 U.S.C. §§ 102 or 103.441
The result is that the Board rejected the claim under 35 U.S.C. § 112
(indefiniteness), but reversed the examiner’s prior art rejection. 442
One take-home lesson is that an attorney or agent needing to include a
functional element in a claim can make the claim more resistant to prior art
rejections can do so by drafting the functional element in a way that is ambiguous.
However, this advice is not practical, since an attorney would not want to
intentionally draft ambiguity into a claim. A better approach is to ensure that all
functional elements are free of ambiguity by making sure that the functional element
is adequately defined in the specification.

433 Id.; see also Ex parte Krick, No. 2009-007641, 2010 WL 3702395, at *1, *4 (B.P.A.I. Sept. 20,
2010); Ex parte Boyle, No. 2009-006121, 2011 WL 2491027, at *3 (B.P.A.I. June 20, 2011); Ex parte
Box, No. 2010-001179, 2012 WL 359938, at *3 (B.P.A.I. Jan. 31, 2012).
434 Application of Wilson, 424 F.2d 1382, 1385 (C.C.P.A. 1970).
435 Newman, 2002 WL 851849, at *2.
436 Id. at *3.
437 Id.
438 Id.
439 Id. at *4.
440 Id. at *3.
441 Id. at *4, *5.
442 Id. at *3.
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B. Indefiniteness rejections against functional elements that are a mélange of a device
claim and methods claim.
When drafting a functional element, an occasional mistake is that the functional
element turns out inadvertently to require performance of an action. In other words,
the claim is a mélange of a claim to a device and also a claim to a method of using the
device. This confusion was an issue in Ex parte Johnston,443 Ex parte Di Francesco,444
and Ex parte Hahn-Carlson.445 The result can be a rejection for indefiniteness under
35 U.S.C. § 112(b).446 The disputed claim in Ex parte Johnston was as follows. The
associated structure is “rigging”:
[Claim] 1. A triangulated mobile gantry crane, comprising . . . rigging that
extends downwardly from the beams . . . the rigging lifting the load from
the ground upon subsequent extension of said booms and that then
being releasable from the load upon subsequent retraction of the
said booms.447
The Board held that “it is not clear whether Appellant [inventor] is claiming a
method of loading and unloading in combination with the gantry device or merely
reciting functional language.”448 The result was that the claim was rendered invalid
for indefiniteness.449
The following provides a context that demonstrates the distinctive fact pattern
of Ex parte Johnston. Ex parte Johnston fits into the last of these fact patterns. In
construing a claim to a device or composition, the Board encounters an element that
resembles a functional element and then proceeds to take one of the following
decision trees:


Decision No. 1. The Board identifies the element as a functional
element, and then determines if the prior art expressly discloses the
same function;450

443 Ex parte Johnson, No. 2009-004993, 2010 WL 3948080, at *3 (B.P.A.I. Sept. 30, 2010). Ex
parte Johnson provides the useful advice that the standard for indefiniteness is lower in prosecution
than in litigation. Id. This different standard stems from two sources, namely, the presumption of
validity of issued patents, and from the policy of the USPTO to require the applicant to more
precisely define the metes and bounds of the claimed invention, where this requirement takes the
form of indefiniteness rejections. Ex parte Miyazaki, No. 2007-3300, 2008 WL 5105055, at *6
(B.P.A.I. Nov. 19, 2008).
444 Ex parte Difrancesco & Griffiths, No. 2009-013923, 2010 WL 4991485, at *3 (B.P.A.I. Dec. 3,
2010).
445 Ex parte Hahn-Carlson, No. 2010-001876, 2011 WL 3871995, at *2 (B.P.A.I. Aug. 29, 2011).
446 Formerly 35 U.S.C. § 112 ¶ 2.
447 Ex parte Johnston, No. 2009-004993, 2010 WL 3948080, at *1 (B.P.A.I. Sept. 30, 2010).
448 Id. at *3.
449 Id.
450 Ex parte Aflekt, No. 2007-2815, 2007 WL 2823738, at *6 (B.P.A.I. Sept. 27, 2007); Ex parte
Ahnert & Pollak, No. 2009-002287, 2009 WL 2137372, at *3, *4 (B.P.A.I. July 16, 2009); Ex parte
Becker, No. 2008-005716, 2009 WL 1712926, at *8 (B.P.A.I. June 1, 2009); Ex parte Bianchi, No.
2009-009024, 2011 WL 729510, at *5 (B.P.A.I. Feb. 28, 2011); Ex parte Champion & Beatty, No.
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Decision No. 2. The Board identifies the element as a functional
element, and then determines if the prior art is capable of the same
function;451



Decision No. 3. The Board dismisses the element as merely
“intended use” and holds that the element has no patentable
weight;452



Decision No. 4. In evaluating a claim to a device, the Board notices
an element that recites a method that must be performed when
making or using the invention that is encompassed by the device
claim, and consequently holds the claim to be invalid for
indefiniteness.453
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The take-home lesson is that attorneys and agents should ensure that their
functional elements do not appear to require the performance of any particular
method.454
A case from the Federal Circuit, R.A.C.C. Industries, Inc. v. Stun-Tech, Inc., also
discloses an example of, and warns against, claims that are a hybrid of an apparatus
claim and methods of use claim.455 On occasion, rejections from examiners have

2009-003797, 2009 WL 5449478, at *4 (B.P.A.I. Dec. 31, 2009); Ex parte Cooper, No. 2010-000730,
2010 WL 4219748 (B.P.A.I. Oct. 25, 2010); Ex parte Downs, No. 2009-009496, 2010 WL 327314, at *2
(B.P.A.I. Jan. 27, 2010); Ex parte Duckett & Kessler, No. 2009-004516, 2009 WL 2342071, at *3
(B.P.A.I. July 30, 2009); Ex parte Eis & Willmes, No. 2009-005148, 2010 WL 2340160, at *3 (B.P.A.I.
June 9, 2010); Ex parte Emmer, No. 2010-000511, 2010 WL 2547683, at *3 (B.P.A.I. June 23, 2010);
Ex parte Golden, No. 2010-001401, 2011 WL 5116530, at *2 (B.P.A.I. Oct. 21, 2011); Ex parte
Grilletto & Kutlu, No. 2008-3595, 2008 WL 2942158, at *3 (B.P.A.I. July 30, 2008); Ex parte Jones,
No. 2005-2180, 2005 WL 3067958, at *3 (B.P.A.I. Sept. 29, 2005); Ex parte Kim, No. 2009-002842,
2009 WL 2981518, at *6 (B.P.A.I. Sept. 18, 2009); Ex parte Kline, No. 2008-4254, 2009 WL 357784,
at *9 (B.P.A.I. Feb. 12, 2009); Ex parte Kelkar & Malladi, No. 2009-002276, 2009 WL 1904063, at *4
(B.P.A.I. July 2, 2009); Ex parte Mardian, No. 2008-2369, 2008 WL 2321841, at *5 (B.P.A.I. June 5,
2008); Ex parte Mullick, No. 2010-005090, 2011 WL 3872016, at *3 (B.P.A.I. Aug. 29, 2011); Ex
parte Rodriguez & Smith, No. 2009-012248, 2011 WL 3871985, at *2 (B.P.A.I. Aug. 29, 2011); Ex
parte Sanocki, No. 2008-2497, 2008 WL 2553081, at *4 (B.P.A.I. June 25, 2008); Ex parte
Schmieding, No. 2009-009983, 2011 WL 601932, at *4 (B.P.A.I. Feb. 18, 2011); Ex parte Shaw, No.
2010-003526, 2011 WL 4009524, at *3 (B.P.A.I. Aug. 31, 2011); Ex parte Sjoberg, No. 2009-003597,
2009 WL 2807784, at *2 (B.P.A.I. Aug. 31, 2009); Ex parte Urban & Cobas, No. 2008-4743, 2008 WL
5054187, at *3, *4, *5 (B.P.A.I. Nov. 26, 2008).
451 Ex parte Aaron, No. 2009-003442, 2009 WL 1940558, at *5 (B.P.A.I. July 2, 2009); Ex parte
Baer & Close, No. 2009-001697, 2009 WL 2007185, at *4–5 (B.P.A.I. July 9, 2009); Ex parte Casey
II, No. 2006-0526, 2006 WL 1665570, at *2 (B.P.A.I. Mar. 21, 2006); Ex parte Dando , No. 2008-4024,
2008 WL 4143442, at *3 (B.P.A.I. Sept. 4, 2008); Ex parte English, No. 2009-003199, 2010 WL
2637984, at *2 (B.P.A.I. June 30, 2010); Ex parte Goncharko, No. 2008-005468, 2009 WL 1719532, at
*5 (B.P.A.I. June 11, 2009); Ex parte Hartmann, No. 2008-3391, 2008 WL 4418279, at *1 (B.P.A.I.
Sept. 29, 2008).
452 Ex parte Warner, No. 2006-1748, 2006 WL 2524303, at *2 (B.P.A.I. Aug. 29, 2006).
453 MPEP, supra note 2, § 2173.05(p)(II)
454 See, e.g., Johnston, 2010 WL 3948080, at *3.
455 R.A.C.C. Indus., Inc. v. Stun-Tech, Inc., 98-1186, 1998 U.S. App. LEXIS 30769, at *8 (Fed.
Cir. 1998).
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alleged that functional elements are indefinite per se. However, the Board does not
accept this per se approach.456
C. Indefiniteness where the functional element is not coupled with any structural
element
A functional element can also attract a rejection for indefiniteness where the
functional element is not coupled with any structural element. This fact pattern
appears in Ex parte Lind.457 Although the Board disagreed with the examiner’s
perception that the structural element was missing, this case is still valuable for
pointing out this potential issue. 458 Ex parte Levy also concerns a claim to a device,
but where the body of the claim consisted only of functional elements. 459 The Board
held that the claim was invalid for indefiniteness (35 U.S.C. § 112).460 The preamble
of the claim did contain one structural element (“detector”). 461 Moreover, it is evident
that the word “detector,” although referring to a structure, only describes the
function (detecting), and fails to require or imply the presence of any particular
structure.462
XIV. INHERENCY-BASED REJECTIONS.
A claim can be rejected for anticipation or for obviousness, where the examiner
alleges that one or more elements is inherent in the prior art. This is an inherencybased rejection. Inherency-based rejections can be directed against a structural
element, against a functional element, or against both elements, as they might occur
in any given claim. Although the topic of inherency is too broad to cover in this
article, the following point must be noted.
The danger of an inherency-based
rejection against a functional element is the rule of In re Schreiber,463 which shifts
the burden to the inventor, where the burden is to prove that the cited prior art does
not possess the function in question. The best way to prove that the cited prior art
does not possess the function, is for the inventor to provide side-by-side laboratory
data comparing the prior art composition or device with the claimed composition or
device. Unfortunately, such data is usually not available to the inventor, and thus,
the inventor is not able to rebut the rejection.

456 See Ex parte Zehner & Uitenbroek, No. 2007-1560, 2007 WL 2383805, at *2–3 (B.P.A.I. Aug.
21, 2007); Ex parte Oberg & Mitchell, No. 2002-0225, 2002 WL 32334597, at *1 (B.P.A.I. June 13,
2002); Ex parte De Paoli, No. 2008-1364, 2008 WL 2878514, at *1 (B.P.A.I. July 25, 2008); Ex parte
Sicking, No. 2000-0523, 2001 WL 1057283, at *1 (B.P.A.I. Dec. 11, 2000); Ex parte Betzold &
Busacker, No. 2011-011011, 2012 WL 3801747, at *1 (B.P.A.I. Aug. 28, 2012); Ex parte Campbell,
No. 2001-1404, 2001 WL 34013819, at *1 (B.P.A.I. Nov. 27, 2001).
457 Ex parte Lind, No. 2003-0117, 2004 WL 77362, at *1 (B.P.A.I. July 9, 2003).
458 Id. at *3.
459 Ex parte Levy, No. 2009-010447, 2011 WL 4528803, at *1 (B.P.A.I. Sept. 28, 2011).
460 Id. at *9.
461 Id. at *8.
462 Id. at *1.
463 In re Schreiber, 128 F.3d 1473, 1478 (Fed. Cir. 1997).

[13:251 2014] Functional Elements in Patent Claims, as Construed by
the Patent Trial and Appeal Board (PTAB)

317

Fortunately, a handful of cases from the Board provide guidance on rebutting
inherency-based rejections against a claim possessing a functional element. Ex parte
Brennan concerned a claim to tissue paper having the function of “a saturation
gradient index of from about 1.0 to about 1.5.” 464 The Board reversed the rejection,
on the basis that the examiner failed to provide “direction offered by the secondary
references to select the parameters necessary to produce the saturation gradient
index.”465 This type of rebuttal seems most applicable to functional elements that
include a value or number. The same sort of rebuttal strategy is set forth in Ex parte
York.466 In Ex parte York, the Board wrote that, “where the parameter optimized was
not recognized to be a result-effective variable, routine optimization would not have
been obvious.”467
A more general approach of rebutting inherency-based rejections against claims
having a functional element is as follows. The general approach is to point out a
glitch in the examiner’s reasoning. This rebuttal approach is exemplified by Ex parte
Fazekas, where the Board held that “the examiner must provide sufficient evidence
or scientific reasoning to establish that there is a sound basis for the examiner’s
belief that the functional limitation is an inherent characteristic of the prior art.” 468
Similarly, in Ex parte Heatmax, the Board reversed the inherency-based rejection,
writing that “[b]ecause the Examiner’s inherency theory is based on mere
possibilities or probabilities, we cannot uphold any of the rejections that rely on Tsuji
[prior art] as inherently disclosing the disputed claim limitation.” 469 Ex parte Quickie
provides yet another fact pattern, where the examiner’s inherency-based rejection
against a functional element was found to be “speculative.” 470
Thus, this general approach is to argue that the examiner has not met the
burden of providing sufficient evidence or scientific reasoning, preferably with an
argument why the cited prior art is not capable of performing the function in
question.
In reviewing the 600 opinions used to prepare this article, the author arrived at
the impression that, in the situation where the examiner imposed an inherencybased rejection against a functional element, it was the case that about threequarters of these rejections were sustained by the Board, and that only a quarter
were reversed. Where the rejection was sustained, the Board appropriately stated
that it was “reasonable to believe” that that the prior art was capable of the function
in question, and that the inventor had failed to rebut the reasonable belief. 471 To
provide another example, where the rejection was sustained, the Board appropriately
stated that, “the Examiner has advanced a reasonable evidentiary basis for finding
that [the prior art] device has all of the structural features required of [the] claims,”
and thus would reasonably be capable of the function. 472 In yet another example, the
464 Ex parte Brennan & Blasubramanian, No. 2011-003613, 2012 WL 4165615, at *1 (B.P.A.I.
Sept. 17, 2012).
465 Id. at *3.
466 Ex parte York, No. 2011-010194, 2012 WL 985687, at *5 (B.P.A.I. Mar. 20, 2012).
467 Id. at *5.
468 Ex parte Fazekas, No. 2010-005303, 2012 WL 3766651, at *3 (B.P.A.I. Aug. 24, 2012).
469 Ex parte Heatmax, Inc., No. 2012-002361, 2012 WL 116926, at *5 (B.P.A.I. Jan. 12, 2012).
470 Ex parte Quickie, LLC, No. 2012-000944, 2012 WL 2316828, at *4 (B.P.A.I. June 15, 2012).
471 See, e.g., Ex parte Lau, No. 2010-002161, 2012 WL 1562289, at *4 (B.P.A.I. Apr. 30, 2012).
472 Ex parte Hall, No. 2011-012631, 2012 WL 1068042, at *3 (Mar. 27, 2012).
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Board observed that the prior art device “bears a striking resemblance to that of the
appellant’s invention, and we see no reason why it is not capable of [fulfilling the
functional element of the claim].”473 As a result, the Board affirmed the rejection. 474
Thus, it is this author’s opinion that the best reason to make conservative use of
functional elements, when drafting claims, is the danger of an insurmountable
inherency-based rejection.
XV. FUNCTIONAL ELEMENTS IN EUROPEAN PATENT CLAIMS.
Where an inventor files a patent with the USPTO, it is frequent also to file a
corresponding PCT patent application. The PCT patent application serves as a placeholder, where the inventor is then given time to make decisions on foreign filings. 475
Typically, after a period of a year or so after filing the PCT application, the PCT
application is then broadcast to patent offices in various countries in Europe, as well
as to Australia, Canada, Japan, South Korea, and China. 476 The advice and
conclusions set forth in this article are likely applicable to patent claims in European
countries, in view commentary on functional elements, from the Boards of Appeal of
the European Patent Office:
functional definitions are widely used and accepted for the definition of
features in claims as long as the person skilled in the art knows, without
exceeding his normal skills and knowledge, what he has to do in order to
obtain said result . . . such a definition by the result to be achieved or by the
function to be fulfilled, indicating what the feature should be there for,
allows for a fair protection for the applicant or inventor.477
In another case from Europe, the Board considered the functional element
“being present in amounts and proportions just sufficient to arrest bleeding.”478 The
Examiner had rejected the claim for lack of clarity (Article 84 EPC) (the European
equivalent of indefiniteness). Regarding this element, the Board wrote that it:
is indeed a functional feature which defines a technical result. However,
said feature constitutes also a testable criterion which has to be satisfied by
the claimed pharmaceutical composition. Its testing might appear prima
facie bothersome, but it is nothing out of the ordinary for the field of
medicines and involves only routine trials. Thus, the adopted functional
language is allowable and in line with the EPO case law (see in particular T
68/85, OJ EPO 1987, 228).479

Ex parte Johnson, No. 96-0776, 1996 WL 1748893, at *5 (B.P.A.I. Aug. 13, 1997).
Id. at *6.
475 See generally MPEP, supra note 2, § 1800.
476 Id.
477 In re Therakos, Inc., No. T1222/07-3.2.02, at 9 (T.B.A.E.P.O. Jan. 26, 2011).
478 In re Queen’s Univ. at Kingston, No. T0893/90-3.3.2, at 4 (T.B.A.E.P.O. July 22, 1993).
479 Id.
473
474
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Thus, the European Board considered and allowed a claim having the functional
element.
On the other hand, the Guidelines for Examination in the European Patent
Office warn that functional elements in claims can result in the claim being rejected
for lack of “clarity.” Regarding rejections for lack of clarity, these Guidelines state
that:
[t]he area defined by the claims must be as precise as the invention allows.
As a general rule, claims which attempt to define the invention by a result
to be achieved should not be allowed, in particular if they only amount to
claiming the underlying technical problem. However, they may be allowed
if the invention either can only be defined in such terms or cannot otherwise
be defined more precisely without unduly restricting the scope of the claims
and if the result is one which can be directly and positively verified by tests
or procedures adequately specified in the description or known to the person
skilled in the art and which do not require undue experimentation (see T
68/85). For example, the invention may relate to an ashtray in which a
smouldering cigarette end will be automatically extinguished due to the
shape and relative dimensions of the ashtray. 480
Thus, the Guidelines warn against claiming an invention by “a result to be
achieved,” that is, by way of a functional element. Rejections for lack of clarity are
often imposed against claims that contain functional elements, as is evident from the
file histories available on www.epo.org, but these file histories also provide guidance
on how to rebut the rejections. The following quotes from a rebuttal in the file
history of European Patent EP1164874. The inventor rebutted the allegation of lack
of clarity, regarding the functional element, as follows:
[i]t is remarked that broadness of the claims by claiming by the result to be
achieved does not necessarily imply a lack of clarity. What is in fact
important is that the claims are reproducible by the skilled man. In that
respect, it is constant jurisprudence that such broad claims are allowable as
long as the man skilled in the art knows without exceeding his normal skills
and knowledge what he has to do in order to obtain said result. This is
precisely the case here.481
Hence, it is the case that the European Patent Office simultaneously praises and
condemns functional elements. The take-home lesson is that U.S. attorneys can be
assured that functional elements are recognized, in Europe, as genuine claim
elements that have patentable weight. But U.S. attorneys should also be prepared to
receive rejections from European examiners, where the rejection alleges that
functional elements cause the claim to lack clarity.

480 EUROPEAN PATENT OFFICE, EUROPEAN PARLIAMENT, GUIDELINES FOR EXAMINATION IN THE
EUROPEAN PATENT OFFICE § 4.10 (Sept. 2013).
481 Communication from Attorney to European Patent Office, European Patent Application No.
00 914 366.0-2114, at 2 (Aug. 28, 2003).
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XVI. CONCLUSION.
Functional elements, also known as functional limitations, are present in patent
claims from all technological fields. Functional elements represent a powerful claimdrafting tool that can increase claim scope. These elements increase claim scope in a
manner similar to that of means plus function claims, but without the constraining
requirement that the “means” in means plus function claims be restricted to
embodiments (and their equivalents) that are disclosed in the specification. Most
commonly, a functional element, when properly interpreted, can mandate or impose a
particular range of structures or chemical compositions of the corresponding
structural element in the claim.
Unfortunately, cases from the Federal Circuit are essentially devoid of guidance
for drafting functional elements, and for construing claims that have functional
elements. But fortunately, a huge number of cases from the Board is available,
where these cases establish consistent guidance for about a dozen recurring issues.
All of these issues are documented in this article.
A primary concern, in drafting functional elements into a claim, is that, the
claim will be rejected for anticipation or for obviousness in view of the prior art.
Specifically, the attorney’s concern is that she will be faced with the need to argue
that the cited prior art does not disclose the function, and that the cited prior art is
not capable of performing that function. To be prepared for this type of rejection, the
attorney or agent should ensure that the specification, as originally filed, discloses
one or more laboratory tests that describe how to measure that function. Also, the
attorney or agent should ensure that the specification, as originally filed, contains
recitations of alternative, narrower functions, for possible use in importing to the
claims by way of an amendment. Moreover, the attorney or agent should be prepared
to ask the client to conduct an experiment that compares the preferred embodiment
of the claimed invention, with the closest possible embodiment of the prior art device
or composition. In the ideal world, this comparative data is conducted prior to filing
the patent application, and is incorporated into the specification.
A secondary concern is that examiners routinely fail to realize that functional
elements, recitations of “intended use,” and recitations of a “workpiece,” have
genuine patentable weight. This article discloses all of the available techniques that
are provided from opinions from the Board for arguing that recitations of functional
elements, intended use, and workpieces, have patentable weight.

